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There are few proven therapies that can protect against the inevitable ischaemia 
reperfusion injury (IRI) that occurs during renal transplantation. IRI increases the 
likelihood of delayed graft function (DGF), which negatively impacts on the long-
term survival of a transplanted kidney. One enzyme of interest, heme oxygenase-1 
(HO-1), degrades heme and protects against the oxidative stress that occurs 
secondary to IRI. Clinical renal recipients with higher HO-1 levels have improved 
graft function post transplant. Heme arginate (HA), a form of hemin, which has been 
used to treat porphyria for over 30 years, has repeatedly been shown to induce HO-1 
in in vivo and in vitro macrophages. It is one of the few HO-1 inducers approved for 
clinical use and healthy volunteer studies confirmed that HA could also safely induce 
HO-1 in humans.  
 
Prior to the formal start of the MD, the University of Edinburgh successfully applied 
to NHS Blood and Transplant for funding to investigate whether giving HA to 
recipients of deceased donor renal grafts prior to transplant could upregulate HO-1 
and whether this had any effect on the function and health of the grafts. This MD 
aims to explain the background behind the proposed study, the process of study 
approval, planning and trial logistics and protocol. This thesis then describes the 
methods of sample analysis, the results and future directions for the HOT (Heme 






The HOT study planning and approval process took eight months and the first 
participant was randomised in January 2012. The study was sponsored by ACCORD, 
a joint company from University of Edinburgh and NHS Lothian, and recruited 
patients from the Edinburgh Royal Infirmary Transplant Unit. The protocol was 
followed to ensure that 40 recipients were randomised blind to either active (two 
doses 3mg kg-1 HA: pre-operatively, day 2) or placebo (NaCl: same schedule).  
 
To ensure that the primary outcome was fulfilled, recipient blood was taken daily for 
peripheral blood mononuclear cells (PBMC) extraction. After further blinding steps, 
the PBMCs were analysed for HO-1 protein and mRNA. The secondary outcome 
measures involved collecting urine for analysis of urinary biomarkers (KIM-1 and 
NGAL), taking renal graft biopsies pre-op and day 5 for renal HO-1 analysis and 
collecting renal function data. DGF was calculated daily. To ensure that all adverse 
event data was captured, the recipients were closely reviewed for 7 days and their 
renal function was monitored for 90 days.  
 
Results 
The final participant was recruited in May 2013 within the predicted timescale and to 
budget. This participant completed follow-up in August 2013. Of the 40 participants, 
three received the infusion but did not receive a transplant and therefore could not 
give primary outcome data. The remaining 37 did and this was analysed. Adverse 
events were equivalent between groups and there were no adverse reactions to HA.  
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HA upregulated PBMC HO-1 protein at 24 hours compared to placebo: HA 
11.1ng/ml (1.0- 37.0) vs. placebo 0.14ng/ml (-0.7- 0.3)(p=<0.0001). PBMC HO-1 
mRNA was also increased: HA 2.73 fold (1.8- 3.2) vs. placebo 1.41 fold (1.2- 2.2) 
(p=0.02).  
 
HA increased HO-1 protein immunopositivity in day 5 renal tissue compared with 
placebo: HA 0.21 (-24- 0.7) vs. placebo -0.03 (-76- 0.15) (p=0.02) and the 
percentage of HO-1 positive renal macrophages also increased: HA 50.8 cells per 
HPF (40.0- 59.8) vs. placebo 22.3 (0- 34.8) (p=0.012). Renal HO-1 mRNA was also 
increased in HA group: 2.02 (0.20- 4.03) fold increase compared to 1.68 (0.75- 
10.39) fold in the placebo group but it was not significant (p= 0.451). 
 
Urinary biomarkers were reduced after HA but not significantly so.  
Histological injury and DGF rates were similar between the groups. 
 
Conclusion 
HA is safe and effective in renal transplant recipients as reported in this phase II, 
randomised, placebo controlled, blinded, single-centre study. The primary outcome 
was achieved and demonstrated for the first time that HA induces HO-1 in peripheral 
and renal macrophages in kidney transplant recipients.  
 
There was also evidence that HA increased HO-1 expression in renal tissue. There 
was no evidence that HA improved renal function or reduced injury as seen in animal 
models but it is recognised that the sample size was small and the study was not 
powered to these endpoints. 
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Larger studies are planned to determine the impact of HO-1 upregulation on clinical 
outcomes and evaluate the benefit to patients at risk of IRI. The plans for HOT2 are 




Lay Summary  
 
When a kidney is transplanted from one patient to another, there is an inevitable time 
period when the organ does not receive blood and is therefore deprived of oxygen. 
This results in a serious disease called ischaemia reperfusion injury (IRI) of which 
there is no cure. The more IRI the kidney suffers, the worse it performs when it is 
transplanted into a recipient. This MD investigated a way to protect kidneys against 
IRI with the goal of offering hope to patients who are at risk of this disease in 
transplantation and, also potentially in other illnesses where a lack of blood flow is 
an issue, such as heart attacks and strokes. 
 
Heme-oxygenase-1 (HO-1) is present naturally in nearly all of our cells. It is an 
enzyme that breaks down harmful waste products into positive protective ones. This 
MD describes the HOT study (Heme Oxygenase-1 in renal Transplantation), which 
used Heme arginate (HA) to try to increase the amount of HO-1 present in recipients 
of kidneys from deceased donors. Previous research has shown that people with 
higher HO-1 levels do better after transplantation and that HA can increase HO-1 in 
animals and healthy volunteers.  
 
40 recipients who were admitted for a potential kidney transplant volunteered and 
were randomised to receive either HA or a saline solution, known as placebo. Once 
the transplant had been performed, blood and urine was taken daily for analysis. A 
sample of the donor kidney was taken before and 5 days after transplant. The trial 
was completed on time and to budget. 
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The HOT study achieved its primary aim and showed that HA was safe. It was also 
effective because it increased the amount of HO-1  in  the  patient’s  blood  and  kidney  
tissue. The kidneys appeared to be healthier and work better after HA but this was 
not as obvious because the number treated was small. 
 
This is exciting news because there are so few other options available to improve 
outcomes in transplantation. The number of people who need kidneys exceeds the 
limited resource and HA may offer a chance to improve the health of kidneys after 
transplant, thereby maximising our supply. Larger studies are planned to see if HA 
really can improve the function of kidneys post-transplant and also to expand into 
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1.1 Kidney transplantation 
1.1.1 Background 
The optimal treatment for the majority of patients with end stage renal disease 
(ESRD) is kidney transplantation. Despite the risks of surgery and subsequent graft 
problems, life expectancy is improved after cadaveric renal transplantation compared 
to life remaining on dialysis, both nationally (Oniscu, Brown et al. 2005) and 
internationally (Wolfe, Ashby et al. 1999). Renal transplantation is also cost-
effective with a positive impact on quality of life (Fiebiger, Mitterbauer et al. 2004). 
 
 
Figure 1-1 Comparison between life expectancies of general population, patients after 
transplant and dialysis patients  (from Dr David Ferenbach, using US RDS data) 
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Organs from living donors demonstrate consistently superior results compared to 
organs from deceased donors regardless of the degree of HLA match (Pratschke, 
Wilhelm et al. 2001). Poor kidney function after transplant, known as delayed graft 
function (DGF), complicates between 5-50% of cadaveric renal transplants, and is 
around 50% more common than after living donor transplants (Quiroga, McShane et 
al. 2006). The inevitable difference in cold ischaemic time (CIT) between cadaveric 
and living donor grafts influences outcome as each additional hour of CIT increases 
the risk of graft failure (Debout, Foucher et al. 2015). DGF is associated with 
prolonged hospitalisation and increased risk of acute rejection. It also has an impact 
on long-term sequelae including reduced graft survival and acute rejection with 
financial implications (Quiroga, McShane et al. 2006, Yarlagadda, Coca et al. 2009).  
 
Unfortunately, most patients with ESRD do not have a living donor available to them 
and the only alternative is cadaveric donation. However, demand for kidneys 
outstrips supply and as a result, the criterion of acceptable donor organs has been 
extended to include organs that previously would have been deemed unsuitable for 
donation. These include organs from older donors and organs donated after 
circulatory death (DCD). The principal difference between DCD and donation after 
brain death (DBD) is the period of warm ischaemia to which the kidney is exposed, 
which is greater in DCD organs. While DCD organs are more vulnerable to injury 
from prolonged ischaemia (Tullius, Reutzel-Selke et al. 2000), DBD organs are not 
risk-free because brain death itself causes rapid and massive up-regulation of a 
variety of pro-inflammatory mediators and acute phase proteins in the prospective 
organ donor (Floerchinger, Oberhuber et al. 2012). In an attempt to reduce the 
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ischaemic time of DCD organs, allocation is weighted in favour of shorter travel 
times. Despite this concern, DCD and DBD kidneys have similar outcomes and DCD 
organs are no longer considered contentious (Doshi and Hunsicker 2007). 
 
1.1.2 Extended criteria donors (ECD) 
The definition of extended criteria donors include donors over 60 years old and 
donors over 50 years old with two of the following; hypertension, cerebrovascular 
accident as cause of death, or pre-retrieval serum creatinine of >15mg/dl (Audard, 
Matignon et al. 2008). 
 
Kidneys from ECD merit transplantation because survival of recipients of such grafts 
is still better than dialysis patients waiting for a standard organ (Ojo, Hanson et al. 
2001, Snoeijs, Schaubel et al. 2010). There is on-going debate about who benefits 
most from ECD organs and whether allocation of these organs should be modified as 
in the Eurotransplant Senior Programme. Across Austria, Belgium, Croatia, 
Germany, Hungary, Luxemburg, the Netherlands and Slovenia organs from deceased 
donors over 65 years old are only allocated to recipients older than 65 years without 
the use of donor HLA typing. The three year graft outcomes from those who 
received an age-matched organ were as good as HLA matched transplants (Cohen, 
Smits et al. 2005). Subgroup analysis shows that the most appropriate people to 
receive ECD kidneys are patients over 60 years old on dialysis or younger diabetics 
(Gaston, Danovitch et al. 2003). Although ECD kidneys are associated with 
significantly more complications, including increased risk of DGF, Fraser et al 
demonstrated no significant difference in five-year survival compared to standard 
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criteria donors. As a result, ECD organs will continue to form an increasing 
proportion of all transplants but research into ways to reduce their associated 
shortcomings is required (Fraser, Rajasundaram et al. 2010).  
 
 
With advances in immunosuppression, acute rejection is now rare and the most 
pressing dilemma in transplantation is how to prolong the lifespan of each organ in 
order to reduce the numbers of repeat transplants and therefore, decrease the rate of 
relisting and dialysis burden. 
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1.2 Ischaemia reperfusion injury in transplantation 
Although donor characteristics are an important predictor of graft function, 
perioperative factors also play a role. During transplantation the kidney inevitably 
suffers a temporary interruption and then resumption in its blood supply. This 
phenomenon is known as ischaemia-reperfusion injury (IRI) and is a significant 
alloantigen-independent cause of DGF.  
 
The pathogenesis of IRI is not fully understood but is likely to represent a network of 
interactions facilitated by oxidative molecules and inflammatory cell mediators 
where activated leucocytes, endothelium and platelets are linked in a vicious circle 
(Devarajan 2006, Kinsey, Li et al. 2008). The release of vasoconstrictors and 
formation of platelet microthrombi disrupt the microvasculature of the kidney, which 
results in further injury (Furuichi, Gao et al. 2006, Basile 2007, Holzen, August et al. 
2008, Kinsey, Li et al. 2008, Kinderlerer, Pombo Gregoire et al. 2009).  
 
Prolonged ischaemia leads to cellular necrosis. In the presence of hypoxia, the ATP 
pump fails, allowing calcium, sodium and water to enter the cells. ATP is broken 
down into the potentially toxic hypoxanthine, which accumulates because it cannot 
be catalysed in the anoxic environment. Endothelial injury leads to a cascade of 
events including leucocyte margination and extravasation, increased expression of 
inflammatory cytokines (IL-1E, IL-2, IL-6 and TNFα) and smooth muscle 
vasoconstriction. Hypoxia itself directly activates many of the pathways common to 
both ischaemia and inflammation (Eltzschig and Collard 2004). 
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When the kidney is reperfused with oxygen, the endothelium is reactivated and the 
damaging cycle is amplified, rather than alleviated (Koo and Fuggle 2000). Although 
restoration of the blood flow is essential to prevent permanent damage to the organ, 
reperfusion causes more damage than ischaemia alone. Liver transplant biopsies 
have more severe histological changes after three hours of ischaemia and one hour of 
reperfusion than ischaemia alone for the same period (Varadarajan, Golden-Mason et 
al. 2004). When oxygen is reintroduced, the excess hypoxanthine is converted to 
reactive oxygen species (ROS), which causes further tissue injury via lipid 
peroxidation, leucocyte activation, expression of MHC molecules, recruitment of 
antigen presenting cells and complement activation (Eltzschig and Collard 2004).  
 
In addition to this inevitable IRI damage, there is also a risk of the no-reflow 
phenomenon in any transplanted organ. This is said to occur when the blood supply 
to an ischaemic organ is re-established but microvasculature blood flow remains 
disrupted. On-going endothelial cell disruption, platelet and leucocyte accumulation 
and aggregation is thought to be responsible (Brodsky, Yamamoto et al. 2002). In 
renal transplantation, the end result is a higher incidence of DGF and a risk of graft 





Figure 1- 2 Flow chart of events during ischaemia reperfusion injury (IRI) (adapted from 
Eltzschig 2004). ROS = reactive oxygen species, NO= nitric oxide 
 
 
The ability of a graft to protect itself from cellular injury is increasingly proposed as 
one of the key determinants of graft outcome, and various approaches have been 
proposed as potential therapeutic interventions. The genotype of a donor or recipient 
may influence an organ’s ability to counter cellular injury and endogenous 
cytoprotective molecules could have a role in altering the impact of IRI (Courtney 
and Maxwell 2008). Both of these factors may influence the long-term survival of 
transplanted kidneys and will be expanded below.  
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1.3 The macrophage in renal IRI 
In the normal kidney, the most prevalent leucocytes are macrophages and dendritic 
cells and they exhibit a diverse range of roles including phagocytosis, antigen 
presentation and cytokine production. As a result, they have important functions in 
innate and acquired immunity, renal injury and inflammation and tissue repair 
(reviewed by Erwig, Kluth et al 2001).  
 
Blood monocytes are the precursors of tissue macrophages and dendritic cells. A 
proportion of the circulating monocytes migrate into normal renal tissue where they 
differentiate into resident monocytes and dendritic cells. Blood monocytes 
participate in the well-recognised process of rolling along the endothelial wall until 
they meet damaged tissue, into which they rapidly migrate in response to 
chemokines and cytokines released by activated endothelial, epithelial and 
mesenchymal cells (Erwig, Kluth et al. 2001). In response to endogenous 
inflammatory signals, the monocytes differentiate into macrophages. The resident 
monocytes and macrophages inhabit the interstitial extracellular compartment, an 
ideal location to respond to signals from either intravascular substances or 
surrounding cells (Cao, Wang et al. 2013). 
 
As mentioned in section 1.2, renal IRI is associated with a deleterious influx of 
polymorphonuclear leucocytes, macrophages and lymphocytes (Kelly, Williams et 
al. 1996, Lee, Huen et al. 2011). Macrophages are responsible for the sterile 
inflammation associated with reperfusion either directly from production of pro-
inflammatory cytokines such as IL-6, IL-12, IL-18 or indirectly though activation of 
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NKT cells and T lymphocytes (Li and Okusa 2010). Macrophage infiltration also 
correlates closely with cell apoptosis (Kluth, Erwig et al. 2004). Early macrophage 
depletion experiments supported this destructive hypothesis, because pre-treatment 
of animals with clodronate prior to IRI resulted in a reduction of pro-inflammatory 
markers and improvements in renal structure and function (Day, Huang et al. 2005, 
Jo, Sung et al. 2006). However, more recent research offers a more complex picture 
of macrophages in renal IRI. In an animal model of IRI, Lee et al identified two 
distinct populations of macrophages. As expected the first cells recruited after IRI 
were pro-inflammatory and pro-apoptotic and their depletion prior to IRI reduced 
subsequent kidney injury. But, macrophages that appeared 3-5 days after IRI aided 
renal tissue repair and their depletion resulted in worse renal injury (Lee, Huen et al. 
2011).  
 
Functionally, macrophages are often defined as M1  or  “classically  activated  
macrophages”  and  M2  or  “alternatively activated phenotype”.  M1 macrophages are 
immune effector cells, which secrete high levels of pro-inflammatory cytokines 
including TNFα and IL-6. In contrast, the later, M2 phenotype is less well defined 
but is involved in wound healing and tissue repair. The M2 phenotype is induced in 
response to IL-4 and IL-13 and results in upregulation of arginase, mannose receptor 
and MHC II, which go on to stimulate endocytosis, antigen presentation and 
endothelial cell proliferation (Cao, Wang et al. 2013). Although this model is 
probably simplistic, it highlights the potential plasticity of macrophages in different 
inflammatory settings. Li suggests that the different phenotypes derive from two 
mechanisms; differentiation of separate subsets of circulating monocytes and also 
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macrophage switching between types in response to cues from the local 
microenvironment (Li and Okusa 2010).  
 
 
Figure 1- 3 Macrophage differentiation in renal IRI (from Ricardo et al, 2008) 
 
Macrophages are involved in both inflammation and repair in IRI making them a 




1.4 Heme oxygenase-1 
As discussed in section 1.2, IRI is characterised by the generation of reactive oxygen 
species (ROS) and increased production of pro-inflammatory mediators. Given that 
endogenous antioxidants are depleted when ischaemic organs are reperfused, it has 
been proposed that treatment with antioxidants might ameliorate IRI. While 
treatment with synthetic antioxidants has had success (Land, Schneeberger et al. 
1994), the utilisation of endogenous antioxidants has also been explored.  
 
Heme oxygenase-1 (HO-1) is a rate-limiting enzyme in the catabolism of harmful 
pro-oxidative and pro-inflammatory heme molecules, which are released 
ubiquitously when cells are damaged (Wagener, van Beurden et al. 2003, Ferenbach, 
Kluth et al. 2010). However, the influence of HO-1 extends beyond reducing cellular 
heme. In addition to its antioxidant and anti-inflammatory effect, HO-1 also has anti-
proliferative, immunomodulatory and anti-apoptotic properties and has a role in 
regulating vascular tone, thereby protecting the vulnerable microcirculation (Amersi, 
Buelow et al. 1999, Kinderlerer, Pombo Gregoire et al. 2009, Richards, Wigmore et 
al. 2010).  
 
It is accepted that HO-1’s  protective  effect  is  mediated  by  the  products  of  heme  
degradation; iron, carbon monoxide and biliverdin/bilirubin, as reviewed by 
(Courtney and Maxwell 2008) and (Kirkby and Adin 2006). 
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Figure 1- 4 Heme breakdown catabolised by HO-1 (adapted from Ferenbach 2010) 
 
Hill-Kapturczak accurately summarises the situation when she states that the 
constituents of the HO-1-catalysed  reaction  are  a  “Dr Jekyll and Mr Hyde- like 
phenomenon”  (Hill-Kapturczak 2002) because each of the molecules involved 
possess injurious attributes in addition to their cytoprotective effects (Farombi and 
Surh 2006).  
x Carbon monoxide (CO) is well known for its toxic effects but at low levels 
it behaves as a regulatory molecule in many different processes. CO 
stimulates the production of cGMP, which modulates various functions such 
as vascular smooth muscle relaxation and inhibition of platelet aggregation 
(Brune and Ullrich 1987). CO, in coordination with HO-1, has a role in nitric 
oxide (NO) regulation and limits NO’s free radical formation while 
promoting its positive vasodilatory effects (Thorup, Jones et al. 1999, Kirkby 
and Adin 2006).  
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CO also stimulates the p38 mitogen-activated protein kinase (MAPK) 
signalling pathway, which is a system involved in responding to stress 
signals. Its activation results in reduced pro-inflammatory cytokines 
including TNFα and increased anti-inflammatory cytokines such as IL-10 
both in vitro and in vivo (Brouard, Otterbein et al. 2000). Pro-inflammatory 
macrophages are also inhibited by this mechanism (Otterbein, Bach et al. 
2000) and further immunomodulation can occur via CO mediated T-cell 
suppression (Pae, Oh et al. 2004). 
 
The cellular mechanisms stated above have successfully translated into pre-
clinical experiments.  Rats exposed to CO before and after transplant had 
decreased inflammatory mediators, improved renal blood flow, preserved 
renal structure and increased survival when compared to control rats (Neto, 
Nakao et al. 2004). Despite the interest, human studies are scarce. As of July 
2014, a trial investigating inhaled CO as a potential treatment for transplant 
recipients was reported on clinicaltrials.gov as suspended pending protocol 
changes. Although there are no current human trials investigating water-
soluble CO–releasing molecules (CORMs), results from animal studies look 
promising (Song, Hoeger et al. 2010).  
 
x Paradoxically, even though bilirubin is harmful to the developing neonatal 
brain (Dore, Takahashi et al. 1999), it is also one of the most powerful 
endogenous antioxidants scavenging peroxyl radicals and inhibiting lipid 
peroxidation (Stocker, Yamamoto et al. 1987).  
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It may also have a role in modulating NO production, which can be both 
beneficial and harmful in IRI. In a rat model of IRI, bilirubin was responsible 
for inhibition of leukocyte adhesion and rolling after upregulation of HO-1 
with hemin (Hayashi, Takamiya et al. 1999). The precursor to bilirubin, 
biliverdin, may also prevent harmful complement deposition (Nakagami, 
Toyomura et al. 1993).  
 
Bilirubin has also been shown to offer protection in an experimental model. 
When isolated rat kidneys were perfused with micromolar doses of bilirubin 
before 20 minutes of warm ischaemia, there were improvements in urine 
output, eGFR, tubular function and histological appearance compared to the 
control group (Adin, Croker et al. 2005).   
 
x HO-1 moderates the potentially toxic free iron by altering iron mobilization 
(Ferris, Jaffrey et al. 1999) and co-inducing ferritin, which binds to iron and 
shields its pro-oxidant and apoptotic effect (Balla, Balla et al. 1992, 
Kinderlerer, Pombo Gregoire et al. 2009).  
 
HO-1, perhaps in conjunction with CO, also protects against inflammation via down-
regulation of adhesion molecule expression (Soares, Seldon et al. 2004) and 
suppression of monocyte chemoattractant protein 1 (MCP-1), thereby reducing 
recruitment and binding of leucocytes (Nath, Vercellotti et al. 2001). In addition to 
its chemoattractant properties, MCP-1 also facilitates the infiltration of monocytes 
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into the renal interstitium and has pro-inflammatory and pro-coagulant properties 
(Courtney and Maxwell 2008).  
 
Besides inducing vasorelaxation, HO-1 also acts on vascular smooth muscle to limit 
its proliferation thereby protecting the microcirculation (Peyton, Reyna et al. 2002).  
 
HO-1 also limits unwanted apoptosis through a variety of mechanisms including 
increased expression of the anti-apoptotic genes Bcl-2 and Bag-1 (Katori, Buelow et 
al. 2002) and by upregulation of the cyclin-dependent kinase inhibitor p21 thereby 
enabling renal cells to resist apoptosis (Inguaggiato, Gonzalez-Michaca et al. 2001).  
 
In another illustration of the importance and adaptation of HO-1, the enzyme is vital 
for myeloid cell maturation and differentiation (Wegiel, Hedblom et al. 2014) and 
drives polarization towards the anti-inflammatory, M2 macrophage phenotype (Weis, 
Weigert et al. 2009, Araujo, Zhang et al. 2012). 
 
As regards transplantation, it is hypothesised that, in addition to HO-1’s  role  in  
helping the kidney resist ischaemic injury, HO-1 can also modulate acute rejection as 
seen in a cardiac xenograft model (Soares, Lin et al. 1998). Otterbein hypothesised 
that the anti-rejection effect is probably due to altered platelet function, vasodilation 
and reduction in inflammation as suggested in IRI pathology (Otterbein, Bach et al. 
2000). Another proposed mechanism is via suppression of the immune response 
through deletion of autoreactive CD4+ T cells (McDaid, Yamashita et al. 2005).  
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HO-1 may also have a role in immunomodulation via regulation of HO-1 specific 
CD8+ regulatory T cells (Andersen, Sorensen et al. 2009).  
 
It is likely that a coordinated response from HO-1 and its reaction components will 
provide maximal defence against transplant IRI (Kirkby and Adin 2006). This is 
supported by experimental findings from Nakao et al, who found that dual treatment 
of rat transplant recipients with biliverdin and CO improved graft function and 
recipient survival compared with monotherapy (Nakao, Neto et al. 2005).  
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1.5 Heme oxygenase-1 in renal IRI and transplantation 
The HO-1 pathway is important to transplantation because there is evidence that HO-
1 upregulation protects the kidney from ischaemia. As the kidney is not normally 
involved in the breakdown of red cells or haemoglobin, it generally has very low 
levels of HO-1 activity (Pimstone, Engel et al. 1971). However, HO-1 mRNA, 
protein and enzyme activity increase as an adaptive response to a variety of noxious 
stimuli that occur during ischaemic renal injury including: heme released from 
intracellular organelles, nitric oxide, increased transcription factors NF-kB and 
MCP-1, growth factors and cytokines (Maines, Mayer et al. 1993, Shimizu, 
Takahashi et al. 2000, Sikorski, Hock et al. 2004). When induced by any of the 








Rat experiments in the 1970s found that renal HO-1 activity increased 30-100 fold 
after heme injection. Maximum enzyme activity was seen at 6-16 hours with a return 
to baseline at 48 hours and at its peak, the HO-1 activity of the kidney exceeded that 
of the spleen (Pimstone, Engel et al. 1971).  
 
In keeping with the renal cytoprotective role of HO-1, graft biopsy specimens with 
lower levels of HO-1 correlated with increased markers of oxidative stress 
(Morimoto, Ohta et al. 2001) and humans who are genetically unable to express HO-
1 entirely or who only express lesser amounts have a higher incidence of renal 
disease (Yachie, Niida et al. 1999, Kawashima, Oda et al. 2002, Exner, Minar et al. 
2004). The first case report of a patient with HO-1 deficiency describes a child with a 
variety of pathologies including anaemia and growth failure but also significant 
microscopic renal disease, demonstrated by tubular dilatation and atrophy, iron 
deposition in tubules, endothelial cell injury and inflammatory cell infiltrate 
(Kawashima, Oda et al. 2002).  
 
The development of a HO-1 knock out mouse in 1997 furthered understanding of the 
enzyme’s importance in renal cytoprotection. The embryos were more sensitive to 
heme damage and the kidneys of HO-1 -/- mice demonstrated iron deposition in 
renal tubules and a chronic inflammation profile (Poss and Tonegawa 1997). HO-1 -
/- mice experienced significantly worse renal injury and 100% mortality when 
challenged with heme proteins compared to HO-1 +/+ mice (Nath, Haggard et al. 
2000). A similarly severe renal injury was seen when HO-1 -/- mice were treated 
with the nephrotoxic agent, cisplatin (Shiraishi, Curtis et al. 2000).  
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In the context of renal transplantation, over-expression of HO-1 in a rat model 
resulted in prolonged graft survival and improved function after extended ischaemia 
(Wagner, Cadetg et al. 2003).  
 
A study of human renal transplants found significant upregulation of HO-1 in post-
reperfusion biopsies compared with pre-reperfusion biopsies and that the level of 
HO-1 in the latter was closely related to initial graft function (Ollinger, Kogler et al. 
2008).  Lemos et al found that HO-1 expression was significantly lower in cadaveric 
kidneys compared to living donors and confirmed  Ollinger’s  findings  that  the  levels  
of HO-1 expression correlated with renal function in the first week after 
transplantation (Lemos, Ijzermans et al. 2003). An example of the complex nature of 
HO-1 induction and activity was highlighted when Nijboer et al found the opposite 
configuration of HO-1 gene expression and that the cytoprotection offered by HO-1 
only appeared to apply to organs from living donors (Nijboer, Schuurs et al. 2004). 
The impact of the HO-1 gene polymorphisms in renal transplantation will be 
discussed in a separate section.  
 
As previously described, macrophages are the predominant HO-1 expressing cells 
(Roach, Moore et al. 2009). In renal IRI models, increased macrophage HO-1 is 
associated with improved outcome (Gueler, Park et al. 2007) and depletion of HO-1 
macrophages results in a greater tubular injury (Ferenbach, Nkejabega et al. 2011). 
Macrophages that overexpress HO-1 display fewer inflammatory characteristics 
including reduced TNFα production. This can be replicated by treatment with CO 
both in vitro and in vivo (Otterbein, Bach et al. 2000).  
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There are multiple pathways in transplant IRI that could be beneficially modified by 
increased HO-1 expression. Thus, it was hypothesised that increasing graft and 
macrophage HO-1 expression would be a therapeutic approach to reduce the impact 
of transplant-associated IRI. 
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1.6 HO-1 induction in renal IRI and transplantation 
In general, induction of HO-1 results in structural or functional protection, whilst 
inhibition has the opposite effect. As expected, given the intrinsic importance of HO-
1, the mechanism is not quite this simple because there are other interlinking 
pathways that are also induced and inhibited in tandem. 
 
The first evidence of the protective effects of HO-1 induction was in a rat 
rhabdomyolysis model when Nath et al used haemoglobin to induce HO-1 in the 
renal tissue. They found that increased levels of HO-1 preserved renal function and 
reduced mortality despite substantial kidney injury (Nath 1992). Since then, a wide 
variety of mechanisms and compounds have been used in animal renal IRI studies 
including cobalt, tin, and heat-shock preconditioning to successfully induce HO-1 
with protective effects (Redaelli, Wagner et al. 2001, Toda, Takahashi et al. 2002, 
Matsumoto, Makino et al. 2003, Nath 2006). Induction of CO by methylene chloride 
had a similar positive effect with improved graft function and reduced chronic 
rejection (Martins, Reuzel-Selke et al. 2005).  
 
In a model of ischaemic renal injury, administration of cobalt chloride pre- and post-
ischaemia increased expression of hypoxia-related genes including HO-1, and 
resulted in reduced tubular damage, reduced macrophage infiltration and improved 
function as seen by reduced creatinine levels. HO-1 levels were elevated for up to 48 
hours after injury and therefore suggested that HO-1 may have a role in recovery as 
well as protection (Matsumoto, Makino et al. 2003). Similar results were seen after 
pre-treatment with tin chloride, which decreased serum creatinine and histological 
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evidence of injury compared to placebo. Correspondingly, when the HO-1 activity 
was blocked by tin protoporphyrin and heme concentration increased, this positive 
effect was abolished (Toda, Takahashi et al. 2002). A review by Akagi et al 
highlighted the many protective aspects of induced HO-1 in different models of 
ischaemic acute renal failure (Akagi, Takahashi et al. 2002).  
 
Tullius et al showed that upregulation of HO-1 in rat renal transplant donors by 
administration of cobalt-protoporphyrin (CoPP) prior to transplant mitigated against 
acute rejection, prolonged graft survival and improved long-term function in 
recipients despite long cold ischaemic times. The upregulation of HO-1 was 
associated with reduced TNFα  and  increased  IFN-J and bcl-x mRNA and therefore it 
was hypothesised that the positive effect may be due to reduced macrophage 
activation (Tullius, Nieminen-Kelha et al. 2002). Another group found that in the 
subset of DBD grafts, upregulation of donor HO-1 by CoPP also improved graft 
survival (Kotsch, Francuski et al. 2006). 
 
Recipient survival was improved and renal injury was reduced when gene transfer of 
a HO-1 expressing adenovirus occurred during the cold storage phase of 
transplantation offering further evidence of HO-1 protection in transplant IRI and 
another potential mechanism (Blydt-Hansen, Katori et al. 2003).  
 
However, despite the significant pre-clinical and observational data demonstrating 
the potential benefit of HO-1 induction, there have been few agents identified that 
are suitable for clinical use in recipients of renal transplants.  
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Curcumin, the active component of turmeric, is under investigation because it has 
been shown to induce HO-1 in hepatocytes and protect against ischaemia (McNally, 
Harrison et al. 2006). However, experience in a renal transplant setting has been 
mixed because, although curcumin improved injury markers and the histological 
appearance of the kidney, this did not translate to renal protection (Hammad, Al-
Salam et al. 2012).   
 
Shoskes et al carried out a randomised, controlled trial in 2005 and found that 
treating the recipient post-transplant with curcumin (as an oral compound with 
another bioflavonoid quercetin) improved the early function of renal transplant and 
reduced acute rejection rates (Shoskes, Lapierre et al. 2005). They hypothesised that 
this protection was due to HO-1 upregulation because curcumin upregulates HO-1 in 
human renal proximal tubule cells in vitro and the active group had increased urinary 
HO-1 (Hill-Kapturczak, Thamilselvan et al. 2001). However despite these positive 
findings, there is no evidence that this has been taken further. A search on 
clinicaltrials.gov in July 2014 for  “curcumin  AND transplant”  lists  only one trial, 
which is for investigating a curcumin-containing preservation solution but this record 
has not been active for two years. 
 
Statins also upregulate HO-1 and initially provided an exciting therapeutic option as 
they are generally safe and well tolerated. However their potential has not been 
realised as the multicentre ALERT trial showed no positive impact on graft function 
as measured by eGFR and graft loss over five years (Fellstrom, Holdaas et al. 2004).  
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In 2001, Salahudeen found that pre-treating human renal proximal tubular epithelial 
cells with hemin (a form of heme) increased HO-1 mRNA and protein expression 
and this pre-treatment prevented cold-storage induced injury of the type experienced 
in deceased donor transplantation (Salahudeen, Jenkins et al. 2001). Yoneya et al 
used another form of heme, hemolysate, to successfully upregulate HO-1 and found 
it ameliorated ischaemic acute injury in rats (Yoneya, Nagashima et al. 2002).  
 
In 2008, Holzen used hemin as a pre-treatment agent in donor rats prior to transplant 
and this resulted in improved recipient graft function when compared to recipients 
whose donors had not received hemin. There was histological evidence of HO-1 
upregulation and a significant improvement in microcirculation perfusion (Holzen, 
August et al. 2008). In 2011, Li et al also used hemin to upregulate HO-1 in rat 
transplant recipients with an improvement in renal function and reduction in 
rejection (Li, Wang et al. 2011).  
 
Our group also found that a form of hemin licensed for human use, heme-arginate 
(HA), was an effective inducer of HO-1 in murine macrophages and renal tissue and 
preserved renal function following IRI (Ferenbach, Nkejabega et al. 2011). These 
experiments showed that aged mice developed more severe renal impairment 
following IRI than matched younger animals. The aged mice had less HO-1 
induction but this could be reversed by treatment with HA, which appeared to protect 
against IRI. This protective effect was lost when macrophages were depleted. Thus 
HA’s  beneficial  effects  appeared to be mediated via monocyte/macrophages in renal 
IRI.  
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The first healthy volunteer trial showed that administration of 3mg kg-1 hemin 
increased the plasma level of HO-1 protein five times and HO-1 activity 15-fold 24 
hours after injection (Bharucha, Kulkarni et al. 2010). A follow-on, randomised, 
placebo-controlled trial confirmed that HA infusion safely upregulated HO-1 in the 
peripheral blood mononuclear cells (PBMC) of healthy subjects (Doberer, Haschemi 
et al. 2010).  
 
The review of HO-1 by Nath in 2006 explored the risks of HO-1 induction and, as 
previously highlighted, acknowledged the potentially harmful nature of the products 
of heme degradation. It has been suggested that while low-level HO-1 induction is 
beneficial, it may be detrimental in excess (Suttner and Dennery 1999). Therefore it 
is important that the optimal level of HO-1 expression is identified to ensure that any 
alteration in upregulation rates result in protection rather than harm. Understanding 
the underlying molecular mechanisms controlling HO-1 expression is therefore 
essential.  
 
HO-1 gene regulation in renal injury is complex with a variety of HO-1 inducers 
using different pathways in different cell types. There are multiple binding sites on 
the HO-1 gene for different transcription factors including; Nrf2, nuclear factor KB 
(NF-κB), specialty protein 1 (Sp1), ATF-2, Elk, Jun, activator protein 1 (AP-1), AP-
2, HIF-1, upstream stimulatory factor (USF), TGF-B1 and IL-6 response elements 
suggesting that any or all of these may play a role in modulating HO-1 induction 
(reviewed by (Sikorski, Hock et al. 2004, Traylor, Hock et al. 2007, Hsu, Chu et al. 
2008, Deshane, Kim et al. 2010).  
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In the mouse, the protein Nrf2 is vital for regulation of the HO-1 gene and is 
responsible for HO-1 induction in response to a range of stimuli including heme and 
is likely to have an important role in humans (Akagi, Takahashi et al. 2002). HO-1 
transcription is tightly controlled and Bach1 is a transcriptional repressor whose 
expression is inversely regulated with HO-1. Further analysis has shown that Bach1 
provides a compensatory mechanism to prevent overexpression of HO-1 in a variety 
of cell types in vitro including skin fibroblasts (Raval, Zhong et al. 2012) and 
monocytes (Paine, Eiz-Vesper et al. 2010). It has been proposed that, at low heme 
concentrations, HO-1 is repressed by Bach1, but at higher concentrations, the heme 
binding sites of Bach1 are inactivated allowing access to a variety of transcription 
factors such as Nrf2 with downstream gene activation (Ogawa, Sun et al. 2001).  
 
Closer investigation of the human HO-1 promoter gene identified two regions that 
are responsible for HO-1 transcription in response to heme (Hill-Kapturczak, 
Sikorski et al. 2003). One of these was identified as a binding site for Jun proteins 
with JunB acting as an activator of HO-1 promoter activity and JunD as an inhibitor 
(Hock, Liby et al. 2007). The same group also identified Sp1 as regulating functional 
activity of the HO-1 gene in renal cells in response to heme (Deshane, Kim et al. 
2010).   
 
Gene regulation in human monocytes/macrophages has also been investigated and it 
is likely that Nrf2 is a key player in regulating expression of many oxidative stress-
inducible genes including HO-1 (Ishii, Itoh et al. 2000, Boyle, Johns et al. 2011, 
Rushworth, Shah et al. 2011).  
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The varied means of HO-1 induction from different inducers makes the process 
complicated and it is clear that this will continue to be explored to try to elicit areas 
of therapeutic intervention.  
 
The overarching theme for HO-1 induction is that it requires a small noxious 
stimulus, which then confers protection against a more substantial IRI insult. This is 
the essence of the pre-conditioning phenomenon, which is explored further in section 
4.2.1 of the discussion.  
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1.7 Heme oxygenase-1 phenotype 
HO-1 inducibility is modulated by a dinucleotide guanosine thymine (GT) repeat 
polymorphism within the proximal promoter region of the HO-1 gene. Although the 
reported number of repeats varies from 12- 40, most human populations have a 
bimodal distribution with alleles being either 23 (short or S) or 30 (long or L) repeats 
(Exner, Minar et al. 2004). There is evidence that long repeats are associated with 
less HO-1 gene expression in vitro in comparison to short repeats (Chen, Lin et al. 
2002) and this is associated with susceptibility to a variety of diseases including 
coronary artery disease, aortic aneurysm and asthma, reviewed by (Doberer, 
Haschemi et al. 2010).  
 
Initial work suggested that this phenotypic difference translated to improvements in 
transplant outcomes because recipients who received organs from S-allele donors 
had lower serum creatinine at one year follow-up (Exner, Bohmig et al. 2004) and 
improved graft survival at five year review (Baan, Peeters et al. 2004). However, 
these genetic association studies have proved difficult to replicate and the phenotype 
incidence varies across populations. A larger study found no evidence that donors or 
recipient genotype had a significant impact on graft or recipient survival in Northern 
Irish populations (Courtney, McNamee et al. 2007) and this has been corroborated 
across different populations including Greece (Katana, Skoura et al. 2010) and 
Finland (Turpeinen, Kyllonen et al. 2007). In fact, the established in vitro results 
were not reproduced in either the larger study by Zhang et al where longer GTn 
repeats did not inhibit HO-1 promoter activity (Zhang, Ohta et al. 2006) or the first 
healthy volunteer study.  
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Doberer treated healthy volunteers with HA and upregulated HO-1 in PBMCs but the 
GTn length polymorphism had no effect on the extent of HO-1 induction. In fact, 
they found the opposite, with HO-1 mRNA higher in the L/L group. They proposed 
that this finding was due to either differences in in vivo or variation in HO-1 
transcription in response to heme. Doberer also suggested that different cell types 
may respond to HA differently and further PBMC subpopulation analysis may be 
required (Doberer, Haschemi et al. 2010). Courtney et al hypothesised that there are 
other protective gene variants or molecules in renal transplantation, which may 
compensate for a genetic predisposition towards lower HO-1 production. This 
ensures that even if the HO-1 genotype could alter the cellular response to injury, it 
may be masked clinically (Courtney and Maxwell 2008). 
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1.8 Hemin and heme arginate 
As discussed previously, although heme is directly toxic to adjacent cells, at non-
toxic concentrations heme and its derivatives deliver potent preconditioning stimuli 
that protect in vitro cells from subsequent exposure to toxic conditions (Balla, Jacob 
et al. 1993, Regan, Guo et al. 2000, Li, Zhu et al. 2009). The protective action has a 
lag of several hours and this may explain why the HOT study is the first translational 
study to use hemin or heme arginate (HA) as a pre-conditioning agent (Balla, Balla 
et al. 1992). 
 
Hemin is the ferric form of heme with a chloride ligand whereas HA (or hematin in 
the United States) is ferric heme with a hydroxide ligand and it is this form that has 
been licensed for use in acute porphyrias for over 30 years with few side-effects (Lu, 
Chen-Roetling et al. 2014). In the UK, it is supplied by Orphan Europe under the 
proprietary name of Normosang.   
 
The chemical formula of HA is; 
C34 H18 Fe N4 O4 or (chloro {7, 12-diethenyl-3, 8, 13, 17-tetramethyl-21H, 23H-porphine-2, 18-
dipropanoato (4-)-N21, N22, N23, N24} ferrate (2-) dihydrogen) and the structural formula is 
shown in figure 1- 6.  
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Figure 1- 6 Heme arginate molecule 
 
Most of the reported adverse events for hemin are attributed to the reaction products 
of ferric heme and this can be reduced by liganding heme to arginine as in HA 
(Tenhunen, Tokola et al. 1987). The most common reported side effect of HA is 
infusion site irritation and swelling due to the hypertonic nature of the solution. To 
counteract this, it is advised that infusions are given into large veins or via central 
access. There have been three recorded cases of overdose; in all three cases, the 
patients received 10 times the recommended amount and all suffered liver failure. 
One required a transplant 
(http://www.medicines.org.uk/EMC/medicine/20795/SPC/Normosang/). 
 
After injection, HA rapidly binds to high affinity heme binding sites mainly on 
albumin and is excluded from most organs (Linden, Tokola et al. 1987). It is 
therefore thought that its primary action is likely to be on vasculature (Lindenblatt, 
Bordel et al. 2004, Belcher, Mahaseth et al. 2006, Holzen, August et al. 2008).  
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In the treatment of porphyria, hematin  and  HA  act  by  inhibiting  of  δ-aminolevulinic 
acid synthase rather than the previously discussed mechanism of HO-1 induction 
(Anderson and Chapman 2005).  
 
Hemin has been of interest for decades; systemic pre-treatment with hemin has been 
shown to be protective in many acute injury models, including kidney, brain, heart, 
gut, and pancreatitis (reviewed in Lu et al 2014) but few have translated to clinical 
studies.  
 
Correa-Costa found that when mouse kidneys were treated with hemin, 346 genes 
were upregulated, including those involved in transcription regulation and DNA 
repair. When the microarray was repeated after renal IRI following hemin pre-
treatment, the gene expression profile altered with increased expression of genes 
responsible for vascular smooth muscle contraction and arachidonic acid metabolism 
and reductions in apoptotic genes (Correa-Costa, Azevedo et al. 2012). It was 
hypothesised that this change in transcriptome may be mediated by HO-1 (Lu, Chen-
Roetling et al. 2014). Alternatively, hemin may have a direct regulatory effect on 
transcription factors and signal transducers including Bach 1 and MAPK pathways 
(Mense and Zhang 2006). Further research is required to elicit the mechanisms 
through which heme gives protection.  
 
 58 
1.9 The HOT Study 
In conclusion, HO-1 induction limits cell injury in vitro, reduces kidney injury and 
protects against IRI in animal transplantation models. HA can safely upregulate HO-
1 in humans and elevated levels of HO-1 improve outcome after renal transplant. 
 
Against this background, the team at University of Edinburgh developed a clinical 
trial to translate these bench findings to bedside. 
 
The aims of the HOT (Heme Oxygenase-1 in renal Transplantation) study were: 
x to determine if pre-treatment of recipients of deceased donor renal transplants 
with HA was feasible and safe. 
x to investigate if HO-1 could be upregulated in the recipient macrophages and 
renal graft tissue by HA. 






Materials and Methods 
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2.1 HOT study logistics 
 
The HOT (Heme Oxygenase-1 in renal Transplantation) Study was a single-blinded, 
randomised, placebo-controlled trial. It was registered on the European Clinical 
Trials database (EudraCT no: 2011-004311-23) and at ClinicalTrials.gov (no: 
NCT01430156).  
 
The aim of the study was to investigate heme oxygenase-1 (HO-1) upregulation in 
the macrophages and renal tissue of renal transplant recipients in response to heme 
arginate (HA) infusion. The study took place in the transplant unit in Royal Infirmary 
of Edinburgh (RIE), recruiting its first participant in January 2012 and continuing 
until 40 participants had been recruited in May 2013.  
 
2.1.1 Trial aims 
In  line  with  CONSORT  guidelines,  the  trial  team’s  first  task  was  to  define  the  HOT  
Study objectives and end-points. It was from this starting point that the HOT study 
developed.  
 
2.1.1.1 Primary objective  
Does pre-treatment of recipients with HA prior to renal transplantation increase HO-





2.1.1.2 Secondary objectives 
Does pre-treatment of recipients with HA prior to renal transplantation increase HO-
1 mRNA in the recipient monocytes/macrophages compared to placebo at 24 hours? 
 
How does monocyte HO-1 mRNA and protein expression change over five days 
after HA/ placebo infusion? 
 
Does pre-treatment of recipients with HA prior to renal transplantation and post-
operatively increase HO-1 mRNA and protein expression in the transplanted kidney 
vs. placebo at day 5? 
 
Does HA treatment reduce histological acute tubular injury in renal allograft vs. 
placebo? To include assessment of acute tubular necrosis (ATN) scores, infiltrating 
leucocyte populations (macrophages, neutrophils, T and B cells), endothelial cells, 
presence of platelet microthrombi and tubular proliferation on the biopsy specimens. 
 
Does HA improve outcome after transplantation by reduced delayed graft function 
rates in HA group compared to placebo?  
 
Can we predict the amount of injury a transplanted kidney has sustained by 




2.1.2 Trial funding  
NHS Blood and Transplant funded the HOT study and the money was secured before 
the author started at the University.  As Chief Investigator (CI), the author was 
responsible for developing the trial concept and logistics, writing the protocol, 
naming the trial, applying for approvals and running the study but not a grant holder.  
 
2.1.3 Sample size and recruitment calculation 
CONSORT state that a sample size calculation should be performed for all clinical 
studies (http://www.consort-statement.org/checklists/view/32-consort/66-title). As 
there was limited data in this field, the calculation was based on a small (n=3) in 
vitro experiment of observed HO-1 upregulation in human macrophages following 
HA treatment. It was presumed that the pre-treatment value would be similar to the 
baseline measurement and the 20PM HA treatment was equivalent to 3mg kg-1 IV 
HA treatment. It was also assumed that the responses were paired. The trial 
statistician used the mean and standard deviation (sd) to calculate the numbers 
required.  
 
Using a two-sided two-sample test with a 5% level of significance and 80% power, 
assuming a mean baseline to 24-hour change of 7.47 and a common sd of 3.87, the 
minimum detectable difference in means would be 3.8 corresponding to a sample 
size of 17 per group. The final sample size of 20 per group allowed for dropouts.  
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Audit data from the RIE transplant unit showed that 75 cadaveric renal transplants 
had been performed between April 2009 and May 2010. Using an anticipated 
recruitment of 60% of all potential participants, it was expected to take 
approximately 12 months to complete. 
 
2.1.4 Trial approval 
The study was planned in line with the principles of the International Conference on 
Harmonisation Tripartite Guideline for Good Clinical Practice (ICH GCP). All 
approval applications were submitted through the IRAS online application system. 
 
After meeting with the Scotland Regional Ethics Committee, a favourable ethical 
opinion was obtained. The study received Clinical Trial Authorisation (CTA) from 
the Medicine and Healthcare Products Regulatory Agency (MHRA) for a phase IIB 
clinical trial. The HOT study fulfilled IIB criteria because it planned to investigate 
the efficacy and safety of HA and was not concerned with dosing requirements (IIA 
criteria). The HOT study protocol v6.3 (appendix A), which provided the instructions 
and framework for running the trial, complied with the Medicines for Human Use 
(Clinical Trials) Regulations 2004. 
 
In order to gain approval from NHS Lothian R&D, the trial required agreement from 
all parties concerned and required negotiations with the research contacts in NHS 
Lothian Pathology Department, NHS Lothian Radiology Department, NHS Lothian 
Pharmacy and support services in the Welcome Trust Clinical Research Facility 
(WTCRF).   
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In February 2013, the Data Management Committee (DMC) recommended that 
participant follow-up be extended and it was decided that this change fulfilled 
substantial amendment criteria as defined by the MHRA. The amendment process 
was completed successfully and the protocol, patient information sheets, GP letters 
and consent forms were updated accordingly.  
 
2.1.5 Trial insurance and indemnity 
The HOT study was sponsored by ACCORD (Academic and Clinical Central Office 
for Research and Development: a joint company from University of Edinburgh and 
NHS Lothian; approval number 2011/R/TR/03 and protocol number 
HOTstudy_Thomas11). The sponsors were responsible for insurance and indemnity 
to cover their liability and the liability of the CI and other staff. 
 
The University insured the CI and the trial team for negligent harm caused by poor 
protocol design and NHS Indemnity covered the RIE. 
 
Orphan Europe accepted limited liability related to the manufacturing and original 
packaging of the study drug and to the losses, damages, claims or liabilities incurred 
by study participants based on known or unknown adverse events, which arose out of 




2.1.6 Trial management 
In  signing  the  Investigator’s  Declaration, the author as CI became responsible for the 
overall conduct of the HOT study and thereby guaranteed compliance with the 
protocol. A delegation log ensured responsibilities could be delegated to another 
member of staff in the event of CI not being available although this was not required. 
All study staff completed appropriate Good Clinical Practice (GCP) training.  
 
The Trial Steering Committee (TSC) was established to supervise progress and to 
review the trial using relevant information from other sources including the DMC. It 
also ensured that the trial was conducted within the GCP guidelines. The TSC 
included the CI, fund holders, trial statistician, sponsor representative and an 
independent Chairperson. The TSC approved the original and all changes to the trial 
protocol.  
 
The DMC comprised three independent members with links to clinical 
transplantation. The author provided monthly reports to them and organised the 
meetings. The role of the DMC was to look at the data from an ethical standpoint 
with the safety, rights and well being of the trial participants being paramount. They 
reviewed the safety profile of the study with particular interest in adverse events. To 
this end, the DMC requested two interim analyses of trial data and after review, were 





2.1.7 Trial documentation 
The Investigator Site File (ISF) contained all the information about the trial and was 
written and maintained by the author (contents list in appendix B). Once the trial 
started recruiting, any protocol deviations were recorded as file notes. The author 
wrote the data collection forms (DCFs) in collaboration with the trial statistician 
(appendix C). All DCFs, reports and other records were designed to maintain 
participant confidentiality and were kept in a secure storage area. Written agreement 
was required for the disclosure of any confidential information to other parties. All 
documentation will be stored for five years in accordance with GCP. 
 
The HOT Study database was written by the author and hosted online by the 
WTCRF (https://www.wtcrf.ed.ac.uk/StudiesV6/Login.aspx?dbid=hot). This method 
of data storage ensured safe and auditable data management. The digital forms 
contained the same fields as the original paper DCFs and the response options were 
limited in order to minimise error during subsequent data entry. Once finished, the 
database was checked by the trial statistician and locked so that only WTCRF IT 
staff could access the form templates. Once the trial started, the author entered the 
data from the DCFs into the database and this underwent quality control at regular 
intervals by ACCORD staff. The author could alter the data until all results were 
inputted when the database was locked again for statistical analysis. This prevented 
anyone from changing results after analysis to ensure transparency. 
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When it was time for the statistical analysis, independent statisticians used the data 
dictionary compiled by the author to ensure only the relevant data was exported. 
 
2.1.8 Trial audit and monitoring  
A  Clinical  Trials  Monitor  from  ACCORD  performed  the  initial  ‘green  light’  
assessment at the start of the study and monitored 11 times during the recruitment 
phase to confirm adherence to GCP. There were also regular assessments of the 
accuracy of the data collection by an independent reviewer using study records and 
case notes as source documents.  
 
The University of Edinburgh laboratories were also inspected and audit procedures 
were put in place. These included calibration of equipment and assessment of 
external apparatus.  
 
In March 2013, the MHRA carried out a routine inspection of ACCORD and the 
HOT study was chosen for closer examination.  This involved an in-depth review of 
the ISF and the related documents, DCFs and their source documentation and 
monitoring paperwork. The author as CI was also interviewed about GCP knowledge 
and trial behaviour. The inspection found there were no serious concerns about the 
HOT Study and the three minor recommendations were adopted. No follow-up 
assessment was required. 
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2.1.9 Investigational medicinal product (IMP) arrangements 
Heme arginate (trade name Normosang) was purchased in bulk from the 
manufacturers Orphan Europe. The drugs were over-labelled with HOT study labels 
identifying them as trial supplies in accordance with the Medicines for Human Use 
(Clinical Trials) Regulations 2004 (examples of labels in appendix 8 of protocol v6.3 
– appendix A.) HA is licensed for the treatment of acute attacks of hepatic porphyria 
(acute intermittent porphyria, porphyria variegata, hereditary coproporphyria) and 
therefore, HA was used outwith the licensed indications.  
 
The HA dose of 3mg kg -1 was decided upon as this is the maximal approved dose for 
treatment of acute porphyria. It is also the dose necessary for transcriptional 
induction of HO-1 in PBMC (Balla, Jacob et al. 2000). The maximum dose was 
capped at 250 mg, which is equivalent to one vial and the dosing table is included 
(appendix 9 of protocol v6.3 – appendix A). Taking advice from the Normosang 
SmPC, the maximum concentration of HA administered was limited at 2.5mg ml-1 in 
order to minimise the risk of phlebitis and pain at the site of infusion. HA was 
diluted in 0.9% NaCl and the total volume of infusion was standardised at 100mls for 
ease and to maintain blinding. The placebo was 0.9% NaCl. 
 
2.1.10 Personnel coordination 
The HOT study required coordination and cooperation from many different 
individuals and departments and it is to their credit that the trial ran so successfully. 
Before the trial started, the study was presented at the unit meeting to inform the 
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relevant individuals and answer questions. Regular e-mails from the author ensured 
that  the  HOT  study  remained  in  people’s  consciousness. 
 
The Transplant Recipient Coordinators, who are experienced professionals 
responsible for the coordination of the transplant, were responsible for contacting the 
author when a potential deceased donor renal recipient was on their way to hospital. 
Once in hospital, the author would liaise with ward nursing staff and the dialysis unit 
to meet the potential participant. If the patient consented, the theatre team, 
anaesthetist and surgeon were contacted to make them aware of the recruitment and 
any potential impact on their work. Biopsies required pathology input and day 5 
biopsy requests were made to a named Consultant in the pathology department. The 
author informed the ward nursing staff and phlebotomy staff about trial participants 
aided by the transplant research nurse.  
 
2.1.11 Day to day trial management 
In addition to the actions in 2.1.10, there were regular essential activities once the 
study started. These included recruiting patients and answering their questions and 
those of their family, taking blood, administering infusions and undertaking clinical 
assessment. If participants agreed to biopsies, these were organised and the 
specimens taken to pathology. Paperwork had to be completed for safety and 




In addition to this, there were regular stock checks of the IMP, paperwork, and 
clinical and laboratory supplies. In the lab, samples were frozen for later batch 
analysis and the fridges and freezers were temperature checked daily.  
 
Occasionally, there were unexpected events, which required urgent action such as 
temperature excursions on the ward drug stock fridge.  
 
Every month, a DMC report was prepared. This reported on recruitment info and 
rates of adverse events. 
 
There were annual reports for the funders, sponsors, MHRA and the Ethics 
committee. Follow-up data was also collected and collated. 
 
2.1.12 Randomisation  
 
The randomisation was done by random, random block, with stratification by donor 
type. This ensured that there were equal numbers of organs donated after brain death 
(DBD) and organs donated after circulatory death (DCD) in each group thereby 
taking into account the most significant risk factor for IRI. The trial statistician 
generated the random allocation sequence and an independent party produced 
sequentially numbered, sealed, opaque envelopes, which were only opened by the CI 
after consent had been given. The date and time of the randomisation was witnessed 
and recorded. Once opened, the envelopes were stored in a remote secure location. 
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2.1.13 Trial safety  
On commencement in the trial, all participants were seen daily during their 
admission by a member of the trial team and questioned about potential adverse 
events (AEs). Particular attention was given to the known side effects of HA, listed 
in the SmPC (appendix 1 of protocol v6.3- appendix A).  
The HOT study used the following GCP definitions. 
x An adverse event (AE) is any untoward medical occurrence in a clinical trial 
participant, which does not necessarily have a causal relationship with the 
IMP, (HA in the HOT study). 
x An adverse reaction (AR) is any untoward or unintended response to IMP, 
which is related to any dose administered to that participant.  
x An unexpected adverse reaction is an adverse reaction that is not consistent 
with the SmPC for IMP. 
x A serious adverse event (SAE), serious adverse reaction (SAR) or 
suspected unexpected serious adverse reaction (SUSAR) is any AE, AR or 
UAR that at any dose: 
x results in death; 
x is life threatening; 
x requires hospitalisation or prolongation of existing hospitalisation*; 
x results in persistent or significant disability or incapacity; 
x is a congenital anomaly or birth defect. 
 
* Given that all patients in the HOT study were hospitalised and left the trial at discharge, 
only prolongation of stay was applicable to the HOT study.   
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Many of the participants were in poor health pre-operatively and certain post-
operative events were expected so the decision was made to limit the AEs recorded. 
These exemptions are recorded in protocol v6.3 (appendix A). The author was 
responsible for the detection and documentation of AEs and participants were 
instructed to contact medical staff with any new symptoms (AE reporting log form, 
appendix D). 
 
If  any  AE  met  the  regulatory  criteria  of  SAEs,  it  was  reported  in  detail  in  that  day’s  
DCF and on a separate SAE form (appendix E). The author assessed for seriousness, 
expectedness and causality as defined in the protocol. Any AEs/SAEs judged as 
having a reasonable suspected causal relationship to HA were considered as related 
and therefore classified as adverse reactions or serious adverse reactions 
(ARs/SARs).   
 
In line with GCP, SAEs were reported to the sponsors within 24 hours. After 
recording an AE or recording and reporting an SAE, the participant was followed up 
until the end of the trial. SAEs still present in participants on the day of discharge 
from the trial were monitored until resolution of the event or until no longer 
medically indicated and a follow-up SAE report was completed. The ACCORD 
Research Governance & QA Office reported SAEs to the co-sponsors (Edinburgh 





In the event of a SUSAR occurring when the CI was unavailable, a pharmacist could 
authorise an emergency unblinding and for this reason, the pharmacy department 
held  copies  of  the  patient’s  randomisation  status  in sealed envelopes.  
 
All staff complied with the requirements of the Data Protection Act 1998 with regard 
to the collection, storage, processing and disclosure of personal information. Access 
to collated participant data was restricted to those clinicians treating the participants. 
Computers were password protected and did not contain patient identifiable data.  
 
2.1.14 End of Study 
The end of the active component of the study was defined as post-operative day 7 for 
the 40th participant. However, the follow-up blood results at day 30 and day 90 were 
recorded in line with the DMC request.  
The end of the study was reported to the REC and MHRA within the 90-day limit 
and the summary reports were provided within the 1 year time limit.
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2.2 Clinical components of HOT Study  
2.2.1 Clinical interactions 
In December 2011, all patients on the East of Scotland kidney transplant waiting list 
received a letter about the trial (Patent Information Sheet- appendix 5 in protocol 
v6.3; appendix A). Another mailing was sent to all new additions at trial midpoint. 
The author was available during office hours to answer patient questions and some 
patients made contact to discuss the trial and its impact. Patients had the option to opt 
out of the trial in advance. The author met all of the remaining patients once they 
arrived in RIE for their transplant to assess for eligibility.  
 
All RIE transplant patients are over 18 and there was no upper age limit to the HOT 
Study. A patient was ineligible for inclusion in the study if: 
1. they were unable to receive the standard immunosuppressive regime  
2. they were unable to give informed consent 
3. they had a known hypersensitivity reaction to HA  
4. they were receiving more than one organ 
5. it was their 3rd or subsequent kidney transplant 
6. they were fully anticoagulated pre-operatively 
7. they were on combined anti-platelet agents 
 
Patients who fulfilled criteria 6&7 were exempt to reduce the risk of bleeding 
complications from the day 5 renal biopsy.  
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All potential participants who met inclusion criteria had consort data recorded 
anonymously including gender, age, type of transplant, and reason for ineligibility or 
non-recruitment. This was recorded on the initial contact form (DCFs; appendix C). 
 
Signed informed consent was obtained and the participant received a copy (appendix 
4  in  protocol  v6.3;;  appendix  A).    A  letter  was  also  sent  to  the  participant’s  GP  to  
inform them of the participation (appendix 6 in protocol v6.3; appendix A).  Patients 
could withdraw from the study at any point without affecting their treatment. 
 
Once the patient had consented, they were assigned a participant number and 
randomised by opening the corresponding envelope. In order to eliminate bias, 
consent preceded randomisation. The appropriate drug was then prepared.  
 
There were two arms in the study: 
x Arm A 
This group received an infusion of 3mg kg-1 HA diluted in 100ml 0.9% saline over 
30 minutes into a large peripheral or central vein prior to transplant surgery and 
again, on day 2.  Both infusions were followed by another 100mls of saline to flush 
the cannula and vein. 
 
x Arm B (control group) 
This group received an infusion of 100ml 0.9% saline over 30 minutes into a large 
peripheral or central vein prior to transplant surgery and again, on day 2.  Both 
infusions were followed by another 100mls of saline to flush the cannula and vein. 
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HA stock was held in RIE pharmacy and in a secure fridge in the transplant unit for 
administration out of hours. HA is a dark green solution and therefore, to ensure 
blindness, all infusions were administered through opaque bags and giving sets. Only 
the author, who was responsible for administering the trial drug, was aware of the 
nature of the infusion. Once randomised, the infusion was prepared and given 
immediately. 
 
Blood samples were taken to measure the HO-1 expression in circulating 
macrophages/monocytes immediately prior to transplant (baseline), 24 hours later 
(day 1), prior to the second dose of HA/placebo (day 2) and day 3 and day 5 post- 
transplant. This mapped HO-1 expression over time. The window for the first post-
transplant blood sample was 20-28 hours post infusion to avoid patient disruption 
overnight and allow for staff work planning. Once the blood had been taken, the 
samples were processed in the Queen’s  Medical  Research  Institute  (QMRI).  
 
Two renal biopsies were performed: prior to implantation on day 0 (baseline) and 
day 5 (the recommended time for diagnostic renal biopsy). The pathologist examined 
the specimens for renal injury and HO-1 induction was determined using 
conventional laboratory investigations.  
 
Daily, early morning urine samples were collected to detect urinary biomarkers.  
 
All participants received standard post-operative care and standard 
immunosuppressive triple therapy.  
 77 
2.2.2 Clinical data collection 
All participants had a HOT Study checklist completed to ensure that the appropriate 
trial procedure was followed and fulfilled (DCFs- appendix C). 
Background information was obtained from the patient and their medical notes. It 
included (but was not limited to) participant weight, indication for transplant, 
number of previous transplants, current medication, smoking status and alcohol 
history. The need and timing of pre-operative dialysis was also recorded. 
 
Donor data collected included type of donor (DCD vs. DBD), medication, cause of 
death and ischaemic times. This information was available from the transplant 
coordinator.  
 
Information was also gathered from the operation note and the anaesthetic chart. This 
included cold and warm ischaemic time, quality of reperfusion, ASA grade, the 
duration of surgery with the estimated blood loss, minimum blood pressure and the 
need for transfusion. Each infusion had a DCF, which recorded the timings and 
completeness of the infusion. 
 
The participants were reviewed daily to monitor recovery and for evidence of post-
operative complications. This data and relevant blood results were recorded on 





In the HOT study, delayed graft function (DGF) was pre-defined as an increased or 
stable serum creatinine, or a decrease of less than 10% per day in 3 consecutive days 
in the first week after transplantation. Participants were followed up for seven days 
post-transplant or until discharge from hospital, whichever was sooner. Participant 
journey is shown in figure 2- 1. 
 
 
2.2.3 Clinical follow-up  
 
The DMC recommended that follow-up blood results for all participants be recorded 
including day 30 and day 90 creatinine, eGFR, haemoglobin (or as close to these 
dates as possible.) Readmissions within 30 days of transplant and dialysis status were 
also recorded. This information did not require additional patient contact and all 

















































































































































































































































































































































































































2.3 HOT Study sample analysis 
 
All the processes below were developed as Standard Operating Procedures (SOPs) 
and approved by QMRI management and ACCORD staff in line with Good 
Laboratory Practice (GLP) guidelines for CTIMPs. All documentation was available 
in the Investigator Site File (ISF) for the HOT Study.  
 
Samples were stored anonymously, only identifiable by a unique, sequential trial 
number. Participant samples were stored in an individually labelled box in the -800C 
freezer, for which the temperature was checked and logged. All histological slides 
were labelled with the trial number and stored at constant room temperature in a 
secure cupboard. All reagents used in the HOT study analysis were stored in a fridge 
at 2-4qC, for which the temperature was checked and logged. 
 
As the author also performed the laboratory analysis, a further blinding process was 
required to eliminate any potential bias. To this end, an independent lab member 
blinded the samples prior to analysis. Once the samples had been analysed, the 
laboratory results were entered into the database under the blinded number. At the 
end of the trial, the independent lab member sent the statistician the blinding code to 




2.3.1 Peripheral blood mononuclear cells (PBMC) analysis 
PBMC were extracted from whole blood using the Dextran and Percoll gradient 
method (de Almeida, Silva et al. 2000).  
 
2.3.1.1 Method for PBMC extraction from whole blood 
40ml of whole blood was collected by participant venepuncture and transferred to a 
50ml Falcon tube containing 4ml of chelating agent (3.8% sodium citrate). After 
mixing, the anti-coagulated blood was transported to the laboratory for processing.  
 
First, the blood was centrifuged to separate it into its constituent parts. The gold, 
platelet rich plasma (PRP) top layer was removed and 220Pl of 1M CaCl2 was added. 
After 1 hour in a 370C water bath, the platelets were fully aggregated and the purified 
serum was decanted into labelled microcentrifuge tubes for storage at -800C. 
 
Next, the leukocytes were separated from erythrocytes by Dextran sedimentation. 
6ml warmed Dextran (GE Healthcare, UK) was added to the remaining cell layer, 
made up to 50ml with warm NaCl and mixed. This was left to stand for 20-30 
minutes, during which time the erythrocytes sedimented. The upper layer containing 
the cells of interest could then be transferred to a fresh 50 ml tube, which was filled 
to 50ml with NaCl and centrifuged, in order to isolate the cells.  
 
The PBMCs were separated from other leucocytes using a Percoll gradient. The 
Percoll stock solution was diluted with phosphate buffered saline without Ca2+/Mg2+ 
(PBS) to form three different solutions of 81%, 68% and 55% concentration.  
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The gradient: 3ml of 81% Percoll was added to a 15ml Falcon tube. In order to 
maintain distinct layers, 3ml of 68% Percoll was slowly poured along the inside of 
the angled tube. The final upper layer was formed by resuspending the centrifuged 
cells in 3ml of 55% Percoll. This solution was then layered on top of the 68% Percoll 
layers as before. The gradient was then centrifuged for 20 minutes to separate the 









mononuclear cells (55%/ 68% interface) 
 
granulocytes (68%/ 81% interface) 
 
residual erythrocytes pellet at the bottom 
Figure 2- 2 End result after separation of cells by Percoll gradient 
 
The mononuclear cells were then removed and washed twice in PBS to remove any 
remaining Percoll. The cells were resuspended in 10ml PBS and counted on a 
haemocytometer. The cell solution was then divided into the optimum numbers of 
cells (as determined by previous experiments) for downstream use. 3 tubes of 4x106 
cells were apportioned for RNA analysis and 5 x106 for protein extraction. Any 
remaining cells were pelleted, then resuspended in 2ml of freezing solution (10% 
dimethyl sulphoxide {DMSO} and 90% foetal calf serum {FCS}), before being 
rapidly frozen in a cryofreezer and stored at -800C.  
To confirm the presence of the required monocytes/ macrophages in the isolated cell 
samples, immunohistochemistry and flow cytometry was performed on a random 
selection of samples. 
 83 
2.3.1.2 Method for cytospin 
Purified PBMCs were visualised directly to confirm population type. A solution of 
1x105 cells/ml was transferred onto four slides by performing a cytospin. The slides 
were fixed in methanol. Two of the slides were stained by dipping into Quick-Diff 
red dye (Reastain, Reagena, Finland) for 1 minute, washing and then Quick-Diff blue 
dye for another minute. After rinsing the slides, microscope examination verified the 
population. The other two slides were reserved for HO-1 and CD68 staining (a 




Figure 2- 3 Cytospin images 
a) Quick diff stain of isolated PBMCs with macrophages (x40 magnification)  







2.3.1.3 Method for Flow cytometry  
Small samples of the PBMC and the neutrophil populations were analysed on 
the flow cytometer (BD, USA). The results were gated for different cell types 




Figure 2- 4 FACS images showing cell population 
a) PBMC population 




2.3.1.4 Method for RNA isolation and cDNA synthesis 
The Bioline ISOLATE II RNA Mini Kit (Bioline, UK) was used and the protocol 
was followed. Kit solutions are highlighted in bold. 
Cells from 2.3.1.1 were centrifuged, the supernatant removed and 450Pl lysis buffer 
added to each sample. Each sample was then resuspended and incubated at room 
temperature for 3 minutes. Once homogenised, the sample was stored at -200C until 






Cells mixed with lysis buffer 
and vortexed 
(*frozen until required) 
To disrupt cell walls, plasma membranes and 
organelles in presence of guanidinium 
thiocyanate to deactivate RNases 
Ð Ð 
Lysate filtered through column To reduce viscosity and clear lysate 
Ð Ð 
70% ethanol added To adjust RNA binding conditions 
Ð Ð 
RNA bound onto column To bind RNA to silica membrane in column 
Ð Ð 
silica membrane desalted To remove any salt that may reduce DNase 
activity 
Ð Ð 
DNase added To digest any contaminant genomic DNA 
Ð Ð 
Washed x3 To remove any impurities such as salts, 
metabolites and cellular components 
Ð Ð 
RNA and DNAse free water 
added 
To extract RNA for downstream analysis 
 
Figure 2- 5 Process for RNA extraction from PBMC 
 
The concentration of RNA in ng/Pl was measured at 260nm by spectrophotometer 





The integrity of RNA was randomly tested by agarose denaturing gel. 4Pg of a 
random RNA sample was run through a gel stained with Ethidium Bromide to 
visualise the ribosomal RNA bands. An optimal RNA sample contained distinct 
bands at 18S and 28S, with the latter twice as intense as the former.  
 
500Pg RNA was transformed into cDNA by reverse transcription using the High-
capacity Reverse Transcription kit (Applied Biosciences, UK). The master mix for 
reverse transcription was prepared on ice using the components below (table 2- 1) 
and multiplied by the number of samples to be analysed (+2).  
 
Table 2- 1 Components for reverse transcription reaction 
Component Volume (Pl)/reaction 
10 x RT buffer 2.0 
25 x dNTP (100mM) 0.8 
10 x Random primers 2.0 
Multiscribe reverse transcriptase 1.0 
RNase Inhibitor 1.0 
Nuclease free water 3.2 
Total per Reaction 10.0 
 
10Pl of RNA (diluted with RNase and DNase free water if required) was mixed with 
10Pl master mix. The samples were loaded into the Thermocycler (Biorad, USA) and 





Table 2- 2 Reverse transcription protocol   
 Step 1 Step 2 Step 3 Step 4 
Temperature 250C 370C 850C 40C 
Time 10 mins 120 mins 5 mins ∞ 
The end result cDNA was stored at -800C for later batch analysis.  
 
2.3.1.5 Method for quantitative Real-Time Polymerase Chain Reaction 
(qRT-PCR)  
The cDNA was defrosted on ice and standardised to 100ng in 20Pl with nuclease-
free H2O. An independent lab member randomised the diluted samples. Universal 
PCR TaqMan Master Mix and TaqMan Gene Expression Assays (Life Technologies, 
UK) were mixed as per protocol instructions and multiplied by number of samples to 
be analysed (+2). 
 
Table 2- 3 Components for PCR reaction 
Component Volume (Pl)/reaction 
Master Mix 12.5 
HO-1-FAM assay 1.0 
18s-VIC assay (endogenous control) 1.0 
Nuclease free water 5.5 
Total per Reaction 20.0 
 
5 Pl of each sample was added in duplicate to a 96-well plate stored on ice. 
Reference standards (cDNA from HA treated macrophages, cDNA from placebo 
treated macrophages and pure RNA) were also loaded and two wells were left blank. 
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20Pl master mix was added per well. The plate was covered with an adhesive seal 
and centrifuged before being read on an ABI 7900 PCR machine in University of 
Edinburgh  SURF  facility  using  the  “Absolute  qualification”  standard  programme.  
Once the baseline and threshold values had been defined, the 18s and HO-1 CT 
values were saved and exported. If identical replicates had a CT standard deviation 
>0.3, the accuracy of the data was questionable and the PCR was repeated.  
The mean CT values for each sample were added to the database where the following 
calculations were performed.  
 
Delta (Δ)  CT was calculated for each sample by normalising HO-1 to the control 
gene 18s:  
ΔCT = CT.HO-1 - CT.18s 
 
The ΔΔCT value for each time point (time x) including baseline was calculated by the 
equation:  
 
ΔΔCT = (CT.HO-1 - CT.18s).time x - (CT. HO-1 - CT.18s). baseline 
 
ΔΔCT for baseline should always be 0. 
 
The fold change in HO-1, normalised to 18s and relative to the expression at 
baseline, was calculated for each sample (including baseline) using the equation 
below:  
amount of HO-1 = 2 -ΔΔCT 
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Using this calculation, the value of the mean fold change at baseline should be 1. If 
this was not the case, the calculations were highlighted and rechecked. The equation 
-Δ  ΔCT ensured the exponential raw data (CT) derived from the log-linear plot of PCR 
signal versus the cycle number was converted to a linear form. This ensures that the 
mean fold change in gene expression can be compared by standard statistical tests 
(Livak and Schmittgen 2001). 
 
2.3.1.6 Method for HO-1 protein ELISA  
Cells identified for protein extraction in 2.3.1.1 were centrifuged and the supernatant 
was removed. Cells were resuspended and then lysed. The lysis solution was made 
by adding 1 tablet of protease and phosphatase inhibitors (Sigma, USA) to 10ml 
RIPA buffer (Sigma, USA). The appropriate volume (1ml per 0.5 to 5 x107 cells) 
was added to the cell pellet and vortexed. This was incubated in the fridge for 5 
minutes and then frozen for storage at -800C for future use.  
 
Samples were analysed blind in batch. First, the protein concentration of each sample 
was determined using a Biorad protein assay. The standard curve used BSA (Bovine 
serum albumin) protein standard in concentrations of 2, 1, 0.5, 0.25, 0.125, 0 mg/ml). 
5Pl of each sample and standard was loaded (in triplicate for sample and duplicate 
for standard) onto a 96 well plate. 25Pl of solution A and 200Pl solution B was 
added and the plates were covered and developed on a shaking platform for 15 
minutes. The plate was read at 750nm. The standard curve was calculated ensuring 
that regression analysis showed R=close to 1.  The concentration of the protein lysate 
was documented. 
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The HO-1 Human EIA kit (ENZO, USA) was used as per protocol at room 
temperature and kit solutions are highlighted in bold. The lysate concentration was 
standardised to 1mg/ml using sample diluent if required to ensure a total volume of 
250Pl. The 6-point standard curve was created with HO-1 standard diluted with 
sample diluent from 25ng/ml to 0.78ng/ml.  
 
100μl  sample/  standards  added  to  each  well  on  anti-HO-1 immunoassay plate 
plate sealed and incubated for 30 minutes 
*Ð 
100μl  anti-human HO-1 added to all wells (except blank) 
covered and incubated for 1 hour  
*Ð 
100μl  diluted  anti-rabbit IgG: HRP conjugate added to all wells (except blank)  
covered and incubated for 30 minutes  
*Ð 
100μl  TMB Substrate added to all wells 
covered and incubated for 10 minutes in dark  
Ð 
100μl  Stop solution 2 added to all wells 
Ð 
Read on plate reader at 450nm  
*Wash step; six times with wash buffer  
Figure 2- 6 Process for HO-1 ELISA 
 
The mean of the duplicate absorbance measurements for sample and standards were 
calculated. The mean blank reading was subtracted from all readings. The standard 
curve was calculated and the sample concentrations were extrapolated from it. The 
sample HO-1 concentrations were calculated by multiplying by the dilution factor. 
The data was added to the database. 
 91 
2.3.1.7 Method for Western Blot  
The methods used to detect HO-1 protein by Western Blot are described below. 
Unfortunately, the preliminary results were inconsistent and difficult to quantify. The 
different SOP amendments tried are listed below (table 2- 5) but time restraints 
prevented further modification. Other researchers investigating PBMCs extracted 
from human whole blood echoed this experience. Therefore the Western Blot method 
was rejected and the assay technique described above was used but the methods are 
included for completeness. All steps were completed at room temperature.  
Table 2- 4 Process for making buffers  
Running buffer (Tris-HEPES-SDS)  
makes 10x solution 
x Tris base (MW= 121); 121g 
x HEPES (MW= 238); 238g 
x SDS (MW=288); 10g 
Dissolve in 1L ultrapure water on heating plate 
Transfer buffer (glycine) 
makes 10x solution 
x Tris base; 30.3g 
x Glycine; 144g 
 
Dissolve in 1L ultrapure water  
 Working running buffer  
1x solution 
x 100ml 10x running buffer 
x 900ml H2O 
 
Working transfer buffer  
1x solution 
x 100ml 10x glycine 
transfer buffer 
x 200ml methanol 
x 700ml pure H20 
Tris buffered saline (TBS) 
10x solution 
x Tris; 24.2g 
x NaCl; 80g 
Dissolved in 800ml ultrapure water 
Standardise to pH 7.6 by adding HCl 
Add ultrapure water to final volume of 1L 
TBST 
 
x 100ml TBS x10 
x 900ml ultrapure H20 
x 1ml Tween20 
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2.3.1.7.1 Sample loading  
The proteins extracted as described in 2.3.1.6 were stored in RIPA buffer. The 
volume of protein was known and standardised.  
 
A solution of β-mercaptoethanol and sodium dodecyl sulphate (SDS) was made to 
ratio of 50Pl:1ml. 35Pl of each sample-loading solution was made of 21Pl protein in 
RIPA, 7Pl SDS and 7Pl H2O. 
 
Each sample was heated to 95oC in a heating block for 5 minutes to denature the 
proteins. Each sample was then centrifuged (1 minute at 10,000g) to remove 





Figure 2- 7 Electrophoresis equipment (from Biorad.com) 
 
The equipment was set-up as in figure 2- 7. The 10-well polyacrylamide gel 
(Thermo-scientific, UK) was inserted into position. The middle chamber and 3cm of 
the outer chamber was filled with running buffer to ensure cooling and the sample 
wells in the gel were rinsed thoroughly with running buffer to remove air bubbles. 
7Pl of molecular ladder (Biorad, USA) was added to the left hand lane and then, as 
previously described; 35Pl of sample was added to each well using special gel 
loading tips. Then the remainder of the tank was filled with running buffer. The lid 
was added and current set to 100V, which forces the proteins to migrate through the 
gel at different speeds depending on their length and ensures that the proteins are 
separated by size. Once the samples had nearly reached the bottom of the gel, the 





Figure 2- 8 A gel post-electrophoresis showing how the blue samples containing protein 









2.3.1.7.3 Membrane transfer 
Six pieces of thick filter paper and one piece of membrane (Amersham Hybond ECL, 
GE Healthcare, USA) were cut to the same size of the gel and all were soaked in 
transfer buffer, which had been cooled to 4oC. The gel was also soaked in transfer 
buffer. The semi-dry transfer equipment was set up as in figure 2- 9.  
 
 
Figure 2- 9 Setting up semi-dry transfer equipment (from Benchfly.com) 
 
The surfaces of the plates were moistened with transfer buffer and the gel 
“sandwich”  was  created  taking  care  to  remove  all  bubbles  between  layers.  The  order 
of  the  “sandwich”  was  from  top;; 
x anode plate 
x filter paper x3 
x gel 
x membrane 
x filter paper x3 
x cathode plate 
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The transfer was then run at 15V for 60 minutes to ensure that the proteins were 
transferred from the gel to the membrane. When the run was complete, the transfer 
was confirmed by staining the membrane with Ponceau red dye to detect the protein 
bands (figure 2- 10). The dye was then washed off in TBST.  
 
 
Figure 2- 10 Membrane stained with Ponceau red dye confirming protein transfer. The 
multi-coloured strip at far left is the molecular ladder, which aids protein detection by 
marking size of proteins. 
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2.3.1.7.4 Protein immunostaining 
The membrane was then blocked to remove non-specific binding. The membrane 
was carefully added to a Falcon tube and covered with a protein block solution (1g 
dried skimmed milk in 20ml TBS) and agitated for 20-60 minutes on a roller. The 
membrane was then rinsed three times with 1x TBST. In order to detect the proteins 
of interest, the HO-1 and β-actin antibodies (rabbit polyclonal, ENZO) were diluted 
1:5000 with antibody diluent (0.5g BSA in 50ml TBS + 25ul TWEEN-20 {TBST}).  
The membrane was soaked in antibody solution and incubated overnight at 4oC on a 
roller.  
 
After this, the membrane was washed with TBST five times for five minutes each 
time. Once washed, 10ml of the secondary antibody solution was added with a 
1:2000 solution of goat anti-rabbit horseradish peroxidase (HRP) (ENZO) in the 
same diluent. This was incubated at room temperature for 35 minutes. The solution 
was then removed by washing with TBST three times for five minutes each time.  
 
The ECL substrate solution (Pierce, Thermo Scientific, UK) was made as per the 
instructions and stored in the dark. The membrane was covered in ECL substrate and 
left for 30 seconds. The excess ECL substrate was removed and transported to 
machine in film cassette to avoid exposure to light.  
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2.3.1.7.5 Detection of protein bands 
The membrane was photographed on a Versadoc machine at optimum exposure. The 
images were stored on USB for later analysis on Photoshop. The membrane was then 
stored in TBST for reanalysis later if required. 
 
Figure 2- 11 Images of failed Western Blots with amended protocols 
 
a) 1:5000 primary antibody 
concentration and standard 
development techniques. Only 
3/ 12 wells are visible 
 
red line= β-actin, blue= HO-1 
 
b) 1:2000 primary antibody 
concentration and standard 
development techniques 
 
No discernible difference  
 
 
c) 1:2000 primary antibody 
concentration with super 
strength developer  
 
More protein detected but 





d) Repeated process using 
previously validated samples,  
 
Only 2 wells detected despite 
same samples present in 
other wells 
 
e) Samples from (d) tested 
with super strength developer 
left on for longer 
 
Protein detection was 
improved but inconsistent 
 
f) More protein loaded per 
well (up to 60Pg) with 1:2000 
antibody concentration, and 
superstrength developer left on 
for twice as long.  
 
Best images but inconsistent 
results and membrane burnt 
by long exposure to 






Table 2- 5 Modifications to protocol to maximise and standardise Western Blot results 
Potential explanation for poor results  Attempted solution 
Insufficient protein in each sample Load more protein into each well. 
Made a 40Pl solution: 31Pl protein in 
RIPA, 8Pl SDS, 1Pl H2O 
 
Variation in materials  Standardise conditions with pre-
formed gels and compatible pre-mixed 
solutions (from Thermo-scientific, UK) 
Poor blocking causing excessive background Used BSA instead of milk to block 
 
Insufficient transfer from sample to gel or 
gel to membrane  
Experiment with a variety of timings 
Gel and membrane transfer were run for 
varying times after discussion with lab 
members. 
Insufficient antibody to detect protein Increased concentration primary and 
secondary antibody 
Insufficient or insensitive detection Use of super-concentrated ECL 
substrate detection solutions  
Versadoc digital machine not sensitive 
enough 
Membranes developed using photo 








2.3.2 Renal tissue analysis 
2.3.2.1 Method for renal tissue biopsy 
The baseline biopsy sample was taken during the back table examination of the renal 
graft. A variety of surgeons performed the procedure in a standardised manner 
consisting of two samples from the superior renal pole taken with a 16g core biopsy 
gun. One sample was put immediately into formaldehyde and the other into saline for 
fresh frozen analysis. Both samples were processed in a standard manner by the 
Pathology Department in Royal Infirmary of Edinburgh (RIE). Three extra slides 
were produced from the formaldehyde sample for HOT study analysis. A pathologist 
(or the author if out of hours) divided the fresh sample into a section for standard 
pathology tests and a section for HOT analysis, which was immediately frozen in 
solid CO2. This tissue was transferred to the -800C freezer for long-term storage. 
 
The same sample handling method was followed for the day 5 protocol biopsy. A 
Consultant Radiologist in the RIE Radiology Department performed the biopsy 
under ultrasound guidance.  
 
2.3.2.2 Method for RNA isolation  
Frozen renal tissue was homogenised using rod and needle. As per the ISOLATE II 
RNA Mini kit protocol (Bioline, UK), the lysis solution was added and vortexed. 
From this point, RNA extraction was the same as 2.3.1.4. 
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2.3.2.3 Method for protein analysis 
The initial plan was to analyse renal tissue for HO-1 protein by Western Blot. 
However, this was not possible due to the small size of the biopsy specimens. 
Sample quantification experiments showed that >5mm core sample tissue was 
required for reproducible and accurate protein results. This was only achieved in 
3/37 back table samples. Therefore, immunohistochemistry (IHC) was used to 
quantify HO-1 protein in renal samples. 
 
2.3.2.4 Method for single stain immunohistochemistry (IHC) 
Renal tissue samples were stained for HO-1 using rabbit anti-HO-1 antibody 
(Abcam, USA) with human tonsillar tissue used as positive control. After 
optimisation in the laboratory, the participant slides were stained as a single batch in 
the SURF facility. For each slide, all of the tissue was photographed at x20 
magnification with no overlap. The HO-1 positive area was calculated using 
computer image analysis (Image J, http://imagej.nih.gov/ij). For each Image J field, 
the positive areas (stained brown) were identified and the corresponding number of 
pixels was recorded. The total area of tissue was also quantified using Image J and 
the percentage of HO-1 staining to total tissue area was determined.  
 
2.3.2.5 Method for dual stain immunoflurescence (IF) 
The blinded slides were stained by the SURF facility at University of Edinburgh 
using rabbit anti- human HO-1 antibody (Abcam) and anti-CD68 antibody (Abcam). 
Between four and eight non-overlapping fields at x20 power were photographed on 
the LSM 710 confocal microscope.  
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The total number of CD68 positive cells per field was counted. The number of dual 
stained cells in each field was counted and this was expressed as a percentage of the 
total CD68 cells per field. Then four fields were blindly chosen and their results were 
entered into the database for subsequent statistical analysis.  
 
2.3.2.6 Method for histological assessment 
Histological analysis was performed blind by Dr C Bellamy (Consultant Renal 
Pathologist) using a 13-point system to identify indicators of cell injury.  
The cumulative score divided samples into 5 groups.  
0= no evidence of injury 
1= mild injury 
2= minimal injury 
3= moderate injury 
4= severe injury 
This score was added to the database for subsequent analysis. 
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2.3.3 Urine analysis 
The biomarkers NGAL and KIM-1 were measured in urine samples. 
 
2.3.3.1 Urine collection 
Participant urine was collected from catheter bags and apportioned into 5 x 2ml 
microcentrifuge tubes, labelled with participant number and frozen in -800C freezer. 
 
2.3.3.2 Method for biomarker assay (KIM-1 and NGAL) 
The two biomarkers were analysed using DuoSet human Lipocalin-2/NGAL ELISA 
and DuoSet human TIM-1/KIM-1 ELISA (both R&D Systems, USA). The kit 
protocols were followed and all was performed at room temperature unless stated. 
Kit solutions are highlighted in bold. 
 
Samples were analysed in duplicate and diluted to optimum concentration with 
reagent diluent (R&D Systems). The standard curve used a 7-point dilution of 
recombinant human KIM-1/ NGAL made with reagent diluent with a max 
concentration of 2ng/ml (KIM-1) and 5ng/ml (NGAL).  
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Wells  coated  with  100μl  diluted  capture antibody 
plate sealed and incubated overnight 
*Ð 
300μl  blocking  buffer  (1%  BSA,  Milipore)  added  to  each  well 
plate sealed and incubated for 1 hour 
 *Ð 
100μl  sample/  standards  in  reagent  diluent  added  to  each  well 
plate sealed and incubated for 2 hours 
*Ð 
100μl  diluted  detection antibody added to each well 
plate sealed and incubated overnight in fridge 
*Ð 
100μl  diluted  Streptavidin-HRP added to each well 
plate sealed and incubated for 20 minutes 
*Ð 
100μl  SureBlue TMB Microwell Peroxidase Substrate added to each well 
Plate sealed and incubated for 20 minutes in dark  
Ð 
100μl  stop  solution  (1N  hydrochloric  acid)  added  to  each  well 
Ð 
Read on plate reader at 450nm and 570nm 
*Wash step; three times with wash buffer (0.05% Tween 20 in sterile PBS) 
 
Figure 2- 12 Process for urine biomarker ELISA 
 
 
The mean of the duplicate absorbance readings for sample and standards were 
calculated (450nm). The mean blank reading (570nm) was subtracted from all mean 
standards and samples. The standard curve was calculated and the sample 
concentrations were extrapolated from it. The NGAL/ KIM-1 concentration was 
determined by multiplying by the dilution factor. The results were added to the 
database. 
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2.3.3.3 Method for creatinine measurement 
The QMRI lab measured the creatinine concentration for each urine sample to allow 




2.3.4 HO-1 genotype 
A sample of DNA was extracted from the baseline blood sample. The recipient 
genomic DNA was assayed to determine the HO-1 (GT)n genotype.  
 
2.3.4.1 DNA extraction 
The DNeasy Blood and Tissue kit (Qiagen, USA) was used and the protocol was 
followed. Kit solutions are highlighted in bold. Anti-coagulated blood taken at 
admission was used. 
 
Process Purpose 
100Pl blood, 100Pl PBS and 20Pl 
proteinase K mixed 
 
To lyse cells 
Ð Ð 
200Pl buffer AL added To optimise DNA-binding conditions  
Ð*  Ð 
incubated 560C for 10 minutes To improve cell lysis  
Ð Ð 
200Pl ethanol added To aid binding 
Ð*  Ð 
Add mixture to DNeasy spin 
column and centrifuge 
To bind DNA to silica membrane and 
contaminants pass through 
Ð Ð 
Washed x2 with buffer AW1 & 
AW2 
To remove any impurities such as salts, 
metabolites and cellular components 
Ð Ð 
50Pl Buffer AE added, incubated 
for 1 minute and centrifuged 
To elute DNA for downstream analysis 
 
Figure 2- 13 Process for DNA extraction   *vortex 
 108 
 
The quality and quantity of DNA was determined spectrophotometrically and 
recorded. 
 
2.3.4.2 Method for genotyping 
Fragment length analysis involved amplification of the DNA by PCR using the 
TaqMan PCR kit (Life Technologies, UK) and size analysis using capillary 
electrophoresis (Courtney, McNamee et al. 2007). 
 
The components listed in table 2- 6 were mixed in a RNA-and DNA-free 
microcentrifuge tube and loaded into the Thermocycler machine (Biorad, USA.) The 
primers  (forward:5’-AGA GCC TGC AGC TTC TCA GA-3’;;  reverse  5’- ACA AAG 
TCT GGC CAT AGG AC-3’)  were  modified  with  a  5’-FAM label on the forward 
primer (Invitrogen, Carlsbad, CA) (Exner, Bohmig et al. 2004).  
 
Table 2- 6 Components for PCR reaction 
Component Volume (Pl)/reaction 
Template DNA 2.0 
5PM forward primer 1.0 
5PM reverse primer 1.0 
2PM dNTP 1.0 
10x buffer 1.0 
Taq polymerase 0.125 
Double distilled water  3.875 
Total per reaction 10.0 
 109 
 
Table 2- 7 Programme settings for the PCR reaction 
 Step 1 Step 2 (x 40 
cycles) 
Step 3 (x 41 
cycles) 
Step 4 (x 41 
cycles) 
Step 5 
Temperature 950C 930C 510C 720C 720C 
Time 12 mins 40 seconds 40 seconds 60 seconds 15 mins 
 
The PCR product was diluted to the optimum concentration with triple distilled H2O. 
1Pl of the diluted PCR product and 9PL of internal standard was added to each well 
of the microtitre plate and mixed by pipetting. The internal standard consisted of 
10Pl GeneScan 500LIZ size standard in 1ml HiDi formamide (both from Applied 
Biosystems, USA). Analysis of the samples was performed on an ABI3730 capillary 
sequencing machine at GenePool, a Sequencing and Bioinformatics company at the 
University of Edinburgh. The results were presented as electropherograms, which 
were visualised and interpreted on Peak Scanner software (Applied Biosystems). 
There was one graph for each participant sample. 

































Figure 2- 14 Sample electropherogram; blue peaks are sample product and orange peaks are 
size standard 
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2.3.4.3 Analysing electrophoresis results 
In the electropherogram, the y-axis is relative fluorescent units (RFU) and the 
products in the sample are in base pairs along the x-axis separated by size with 
smallest on left and largest on right. Each graph was analysed to determine the size 
of the allele of interest (the HO-1 promoter allele). Most graphs had a number of blue 
peaks but in each sample, there should be only one (if the individual was 
homozygous) or two peaks (if heterozygous) that represent the true allele. This was 
occasionally complicated by background noise, which had to be excluded. The 
product size of interest was calculated as between 87 and 159 base pairs (bp) based 
on the promoter sequence published by Shibahara (Shibahara, Sato et al. 1989) and 
so any blue peaks outside this range could be ignored as noise. Any peaks that fitted 
the basic allele morphology; a peak with a narrow base and a high RFU, were 
examined more closely. A homozygous allele had a single, tall peak compared to a 
heterozygous individual whose graph had two smaller peaks side by side. The size 
discrepancy is due to the fact that homozygous alleles have all the PCR product 
accumulating at one point, resulting in a higher RFU. The size of the allele (in bp) 
was noted (usually between 103 and 128bp) and the size of the GT dinucleotide 
microsatellite was calculated by subtracting the size of the primers (known to be 
67bp) from the size of the allele. The number of GT repeats was then calculated by 
dividing by 2. This process was repeated for the second peak if heterozygous. 
 
A  participant’s  HO-1 genotype could then be determined. The short allele was 
classed as <25 GT repeats, the long allele >25 repeats. All participants were then 
characterised as either homozygous (SS or SL) or heterozygous (SL). 
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2.4 Statistical analysis 
 
Independent blinded statisticians from the University of Edinburgh analysed the 
HOT study database using the pre-determined endpoints to generate the study report.  
 
PBMC and renal HO-1 expression data, urine biomarkers and infiltrating 
macrophage data were not normally distributed; therefore a non-parametric Mann-
Whitney statistical test was used for these outcomes.  
 
For HO-1 upregulation in renal tissue, a Fisher’s test was used to compare 
percentages between the groups. A comparison of proportions test was used to 
compare rates of DGF between groups. 
A chi2 test was used to look for any evidence of difference in renal tissue injury 
scores between groups. 
Results are presented as median (IQR), mean +SEM or and % values (95% 
confidence intervals) as appropriate. Statistical analysis was performed on SDSS.  
 







3.1 HOT Study results 
 
3.1.1 HOT study recruitment 
The trial began in January 2012 and continued until 40 patients had been randomised 
and received the infusion in May 2013 (figure 3- 1).  
 
 
Figure 3- 1 Flow chart of HOT study recruitment 
 
 
The reasons for ineligibility are included in table 3-1.  
Table 3-1 Reasons for patient ineligibility  
Reason for ineligibility  Numbers  
Unable to receive standard immunosuppression 5 
>2 previous transplants 3 





The renal grafts for the three non-transplanted participants were suboptimal at 
back-table examination and therefore, the transplants were cancelled after the 
infusions had been given. The HOT study protocol stated that once the participant 
had been randomised and given a trial number, it could not be reassigned. As per 
protocol, the patient was observed for the remainder of their time in hospital and 
their baseline data was recorded in the database.  
 
All participants who received a transplant provided a blood sample at 24 hours for 
primary outcome analysis. Due to withdrawal of consent or problems with venous 
access, not all participants gave all blood samples. One participant in each group 
refused the second infusion and all subsequent blood samples. The two participants 
did not withdraw their consent for collection of their clinical data and so remained in 
the trial (figure 3- 2). There were no other withdrawals. 
 
 
Figure 3- 2 Flow chart with breakdown statistics of study blood samples and infusions  
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Five participants in the placebo group and three participants in the HA group 
declined the day 5 biopsy and two in each group were not considered fit or safe for 
biopsy. As a result, there were 10 paired renal samples in the placebo group and 13 









Recruitment rates varied throughout the study period (figure 3- 4) in keeping with 















 .............. Projected          _________ Actual 
Figure 3- 4 Recruitment rates during study period 
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3.1.2 HOT study participants 
 
The baseline characteristics were similar between the groups.  
 
Table 3- 2 Baseline characteristics of the 37 transplanted patients by treatment group 
Characteristic Placebo (n=18) HA (n=19) 
Mean age (range) 52.4 (25-79) 52.1 (21-69) 
Male (%) 11 (61) 12 (63) 
1st transplant (%) 18 (100) 18 (95) 
2nd transplant (%) 0 1 (5) 
Dialysis patient (%) 17 (94) 18 (95) 
Dhx: statin (%) 11 (61) 12 (63) 
Dhx; any antiplatelet agent (%) 8 (44) 6 (32) 





2 (11) 0 
9 (50) 10 (53) 
6 (33) 9 (47) 








Donor characteristics   
Mean age (range) 45.2 (21-73) 46.8 (14- 69) 
Male (%) 13 (72) 10 (53) 
DBD (%) 9 (50) 10 (53) 
DCD (%) 9 (50) 9 (48) 
ECD1 (%) 2^ (11) 4^ (21) 
Mode of organ perfusion- hypothermic (%) 3 (17) 2 (11) 
Mode of organ perfusion- cold static (%) 15 (83) 17 (89) 
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Mean histology score from day 0 sample2 1.8+ 2.2+ 
HLA match  
0 HLA-DRB1 mismatch 
1 HLA- DRB1 mismatch 









Number with virtual crossmatch3 12 (67) 15 (79) 




Mean WIT in minutes5 (range) 36.2 (28- 61) 37.6 (23- 59) 
 
Mean values are given for continuous variables, while numbers of patients (percentages) are 
given otherwise. 
1 Extended criteria donor includes donors > 60 years old or >50 years old with two of the 
following; hypertension, cerebrovascular accident as cause of death, creatinine >1.5 mg/dl 
(132.6  μmol/L) 
2 Score ranges from 1-4 with 1 as least injured and 4 as most, based on 13-point score of 
histological features 
3 Virtual crossmatch= in carefully selected patients that are not sensitised it is possible to 
undertake the transplant without waiting for a full cross match to be performed. This is 
known as a virtual crossmatch, and results in reduced cold ischaemic times. 
4 CIT= Cold ischaemic time= time from storage in ice at recovery to removal from ice during 
transplant operation 
5  WIT= Warm ischaemic time (2nd)= time from removal from ice for transplant to 
reperfusion  




3.1.3 HOT study follow-up 
 
30-day and 90-day follow-up was performed for all participants who received a 
transplant except the one participant in the placebo group who lost their graft due to 
a technical problem.  
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3.1.4 HOT study safety outcomes 
The emergency unblinding procedure was never required.  
No adverse reactions and no deaths occurred during the seven-day trial period.  
 
3.1.4.1 Adverse events 
Table 3- 3 Adverse events within 30-day trial period 
Whole numbers (percentage)  
*Classified as serious and expanded below 
The graft loss was due to technical reasons and they returned to the waiting list. 










(evidence of hypovolemia requiring transfusion) 
1* (6) 2* (11) 
Reoperation/ procedure within 7 day trial 
period. Both events occurred prior to day 5 
biopsy 









Infection requiring antibiotics  
(site recorded below)                             LRTI                               
Urine 
Other 




Systemic Inflammatory Response Syndrome 
(SIRS) 
1 (6) 0 
Acute rejection recognised within 7 days 1 (6) 2(11) 
AV fistula requiring treatment 0 1* (5) 
Graft loss within 7 days 1* (6) 0 
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3.1.4.2 Serious adverse events 
There were five serious adverse events during the trial reporting period: three in the 
placebo and two in the HA group. The sponsors, DMC and MHRA were satisfied 
with the classification and reporting of the events. 
 
Placebo group;  
x One participant had a delayed discharge due to loose stools so the event met 
the criteria of SAE although it was diagnosed as a side effect of 
immunosuppression.  
x One participant was admitted to ITU as a result of acute respiratory distress, 
which was initially diagnosed as a chest infection but then they developed 
pulmonary oedema and atrial fibrillation. They improved within 24 hours and 
made a good post-op recovery once back on the ward.  
x The final participant developed hypotension and was taken to the operating 
theatre twice for exploration of graft. Unfortunately the team were unable to 
repair the renal vein and a nephrectomy was required on day 7. This was 
unrelated to the day 5 protocol biopsy. 
 
HA group (neither was related to the IMP);  
x One participant developed hypovolaemic shock on day 5 and a CT scan 
diagnosed an AV fistula, which was thought to be secondary to the back-table 
biopsy. They required a blood transfusion (two units packed red cells) and 
embolectomy with x-ray imaging. The day 5 biopsy had not been taken. 
x The other participant required transfusion after a localised haemorrhage when 
the drain was removed on day 2. 
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3.2 Effect of HA infusions on PBMCs 
 
In all graphs p value is represented by *.  
****= p<0.0001, *** = p<0.001, **= p<0.01, * = p<0.05. 
 
3.2.1 HO-1 protein expression 
 
The primary outcome measure was the change in HO-1 protein expression in the 
recipient PBMC population from pre-infusion (D0) to 24 hours post-infusion (D1) 
between the placebo group and the HA group.  
 
HA upregulated HO-1 concentration by 11.1ng/ml (1.0- 37.0), compared with 
placebo -0.14ng/ml (-0.7- 0.3) (p=<0.0001) (figure 3- 5). One participant did not 
have a baseline (D0) HO-1 protein measurement so this participant was excluded 
from the primary outcome analysis (n=36). 
 






Figure 2: Treatment with HA upregulated HO-1 protein and mRNA expression in 
















































































































Figure 3- 5 Difference in HO-1 protein expression in PBMC at D1 compared to D0  
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As expected, there was a peak in HO-1 PBMC protein concentration after each HA 
infusion (first infusion given immediately after D0 sample and second after D2 
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Figure 3- 6 Pattern of PBMC HO-1 protein expression over the six days of the study. Each 
coloured line represents a different participant.  
 








Figure 2: Treatment with HA upregulated HO-1 protein and mRNA expression in 




















































































































3.2.2 HO-1 mRNA expression 
The HO-1 upregulation was confirmed by HO-1 mRNA. Delta (Δ) CT values were 
calculated for baseline (D0) and day 1(D1). ΔΔCT was performed to calculate the 
difference in mRNA upregulation at D1 relative to D0. 2-Δ  Δ  CT calculation was 
performed to determine the fold increase from D0 to D1.  
 
HA treatment upregulated HO-1 mRNA expression 2.73 fold (1.8- 3.2) compared 








Figure 2: Treatment with HA upregulated HO-1 protein and mRNA expression in 
















































































































Figure 3- 8 Comparison between HO-1 mRNA upregulation in PBMCs 
 
 
As for HO-1 protein, the pattern of individual (figure 3- 9) and median (figure 3- 10) 
HO-1 expression over the 5-day study was characterised. Although there was also a 
peak in HO-1 mRNA expression after the second infusion, this did not reach 
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Figure 3- 9 Pattern of PBMC HO-1 mRNA expression over the six days of the study. Each 








Figure 2: Treatment with HA upregulated HO-1 protein and mRNA expression in 
















































































































Figure 3- 10 PBMC HO-1 mRNA expression over the six days of the study 
 127 
3.3 Effect of HA infusions on tissue macrophages 
 
After allowing for declined and insufficient biopsies, there were 9 paired renal 







Figure 3- 11 Immunofluorescence images with dual CD68 (green) and HO-1 (red) 
staining in renal tissue from a) D0 HA, b) D0 placebo, c) D5 HA, d) D5 placebo.  Blue= 
nuclear stain. White arrows highlight dual stained cells (x20 magnification) of which one 






There was no significant difference in the numbers of CD68 positive cells between 
treatment groups at either D0 or D5.  
 
At D0, there were 3.50 (1.5- 5.25) CD68 positive cells per high-powered field (HPF) 
in HA group compared to 3.00 (2.25- 4.25) in placebo group (p=0.956).  
At D5, there were 11.0 (4.5- 25.0) cells per HPF after HA compared to 7.38 (4.8- 
























Figure 3- 12 Number of CD68 positive macrophages at D0 and D5 
 
The percentage CD68-positive macrophages expressing HO-1 (so-called dual 
positive cells) at D0 and D5 were compared between groups. As there were no cells 
that only stained for HO-1, the percentage of dual stained cells was calculated using 
the equation:  
 
% dual stained =     number of dual positive cells      x100 
                                 number of CD68 positive cells 
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At D0 there were no dual positive cells in either treatment group.  
At D5, there were 50.81 cells per HPF (40.0- 59.8) after HA treatment and 22.3 (0- 





























Figure 3- 13 Percentage CD68 positive cells that expressed HO-1 (dual positive) at D0, D5 
 
In addition the difference between the % dual stained cells in each paired samples 
was calculated and compared between groups;  
 
Difference = % dual stained D5 - % dual stained D0 
 
This was calculated as a 5% + 30.6 increase in % dual stained cells in the placebo 
group vs. a 46.2% + 24.0 increase in the HA group, which was statistically 
significant (p= 0.007).  
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3.4 Effect of HA infusions on renal tissue 
3.4.1 HO-1 protein expression 
The difference in amount of HO-1 protein expression (as determined by 
immunohistological staining) between back table (baseline, D0) and day 5 (D5) 
samples was calculated and then compared between HA and placebo.  
 
 
There were 10 paired samples in the placebo group and 12 paired samples in the HA 
group suitable for analysis.  
The DAB staining (brown) was quantified as a percentage of total renal protein: 
% renal HO-1 protein =     renal HO-1 protein      x100 
                                                total renal protein 
  
  
Figure 3- 14 Immunohistological staining for HO-1 (brown) in renal tissue at a) D0 HA, 





Then the difference between paired samples was calculated and compared between 
groups: 
 
Difference = % renal protein D5 - % renal protein D0 
 
When HO-1 protein upregulation was expressed as the difference in % HO-1 
expression on D5 compared with D0, HA upregulated protein by 0.21% (0.1- 0.6) 
compared to placebo of -0.03% (-1.3- 0.1) (figure 3- 15 a & b). This was a 
statistically significant difference supporting HA as an upregulator of HO-1 protein 



































































Figure 3- 15 Difference in % HO-1 renal protein between D5 and D0 a) with, b) without IQR  
 
 
In addition, a comparison of proportions test was used to compare the numbers who 
upregulated HO-1 protein in each group (table 3- 4). 30% placebo group (95% CI; 
1.6- 58.4) upregulated HO-1 protein vs. 75% HA group (95% CI; 50.5- 99.5). The 
45% difference (95% CI; 7.5- 82.5) was significant (p=0.08). 
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Table 3- 4 Comparison of proportions of renal tissue HO-1 protein upregulation  
 
 Treatment 
Placebo (n=10) HA (n=12) 
Up-regulation HO-1 protein N % N % 
No 7 70 3 25 
Yes 3 30 9 75 
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3.4.2 HO-1 mRNA expression 
The renal tissue results were analysed in the same way as the PBMC mRNA 
calculations using 2 -ΔΔ  CT method to determine the fold increase of day 5 tissue 
compared to baseline (back table tissue). There was a 2.02 (0.20- 4.03) fold increase 
in the HA group compared to 1.68 (0.75- 10.39) fold in the placebo group. This was 



































In contrast with the protein results, when the comparison of proportions test was 
performed; 53.8% of HA group upregulated HO-1 in renal tissue vs. 60% of placebo 
group. The Fishers test was performed on the difference of 6.2% (CI: -34.5 – 46.90) 




Table 3- 5 Comparison between renal tissue HO-1 mRNA upregulation  
 Treatment 
Placebo (n=10) HA (n=13) 
Up-regulation HO-1 n % N % 
No 4 40 6 46 





3.4.3 Histology  
An independent blinded Consultant Pathologist scored renal tissue samples as per 
previously defined method (section 2.3.2.6).  
  
  
Figure 3- 17 Comparison images of healthy graft kidney at a) x10 magnification, c) x20 
and injured tissue at b) x10 magnification, d) x20 
 
 
There were 21 paired samples for analysis (8 in placebo and 13 in HA group). The 
D0 renal tissue score was compared with D5 score and cross tabulations were created 





Table 3- 6 Cross tabulation of D0 (back-table) and D5 (day 5) biopsy sample pathology scores 























































- - - - 
 
1 17 1 17 
 
- - - - 
Patient 
refused 
2 67 - - 1 17 1 17 1 33 - - 
Inad sample - - - - 1 17 - - 1 33 - - 
0 (no injury) - - - - - - - - - - - - 
1 (mild) 1 33 - - 2 33 - - 1 33 - - 
2 (minor) - - - - 1 17 - - - - - - 
3 (mod) - - - - - - 2 33 - - - - 


























































1 50 - - 
 
- - - - - - 1 50 
Patient 
refused 
- - - - - - - - 2 29 1 50 
Inad sample - - - - - - - - - - - - 
0 (no injury) - - - - - - 1 33 - - - - 
1 (mild) 1 50 1 33 - - - - 2 29 - - 
2 (minor) - - 1 33 - - - - - - - - 
3 (mod) - - 1 33 - - 1 33 3 43 - - 






A further analysis compared D5- D0 scores between groups. A negative result means 
the score improved (D5 kidney was less injured than at D0) and a positive result 
represented deterioration in the health of the kidney at D5. Although you were more 
likely to see an improvement in health of the kidney after HA treatment, there was no 




Table 3- 7 Difference in pathology scores by group. (No -1 score in this analysis.) 
 
Score = D5-D0 
Treatment 
Placebo HA 
N % N % 
















-2 1 13 3 23 
0 2 25 3 23 
1 3 38 2 15 
2 2 25 2 15 




The raw D5 scores were also compared with no significant difference between the 
groups by chi2 test (Fishers p= 0.95) (table 3- 8) or median scores (p= 0.85) (figure 
3- 18). 
 





n % N % 









0 - - 1 7 
1 4 44 4 29 
2 1 11 1 7 
3 2 22 5 36 




























Figure 3- 18 Comparison of D5 pathology score between placebo and HA 
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3.5 Urine biomarkers  
For both NGAL and KIM-1, median raw values for each day were compared 
between groups. A non-parametric Mann-Whitney test was performed and there was 
no significant difference in median biomarkers between groups for either biomarker 
at all days. This was true for both raw values and urinary biomarker: creatinine ratio 
(UBCR) data. Only raw value graphs are shown (figure 3- 19 & 3- 20). 
 
Table 3- 9 Results of urinary biomarker analysis 
 Max value (placebo)  Max value (HA)  P-value 
KIM-1 (raw data) 8.8 + 8.7 4.8 + 3.9 0.17 
NGAL (raw data) 638.5 + 371.2 494.4 + 375.1 0.15 
KIM-1 (UBCR) 2.9 + 4.6 2.6 + 5.7 0.53 





















































Area under the curve analysis was also performed on the maximum raw and UBCR 
biomarker data to assess the usefulness of urinary biomarkers for detecting 
differences between the groups (figure 2- 21). In AUC analysis, the closer the value 
is to 1, the better it is at distinguishing between groups. A value of 0.5 is expected by 
chance. 
 
The KIM-1 raw analysis gave an AUC value of 0.647 (95% CI; 0.447 - 0.847). 
The KIM-1 UBCR analysis gave an AUC value of 0.569 (95% CI; 0.364 - 0.773).  
 
The NGAL raw analysis gave an AUC value of 0.655 (95% CI; 0.460 - 0.850). 
The NGAL UBCR analysis gave an AUC value of 0.443 (95% CI; 0.233 - 0.653).  
 
Therefore, there was no evidence that KIM-1 or NGAL were accurate or useful at 










 1- specifity 
Figure 3- 21 AUC analysis to investigate the value of raw KIM-1 and NGAL for 




In another analysis, participants were subdivided into 2 groups regardless of 
treatment: those with DGF and those without. There was no evidence that either raw 
or UBCR maximum KIM-1 or NGAL values were accurate or useful at predicting 
DGF (regardless of treatment group) (figure 3- 22).  
 
The AUC values were 0.683 (95% CI; 0.472- 0.893) for maximum NGAL and 0.583 









 1- specifity 
Figure 3- 22 AUC analysis to investigate the value of raw KIM-1 and NGAL for 




3.6 Graft function 
 
3.6.1 Delayed graft function (day 7) 
 
The percentage of participants with delayed graft function (DGF) was compared 
between the groups. DGF  was  defined  as  “as  an  increased  or  stable  serum  creatinine,  
or a decrease of less than 10% per day in three consecutive days in the first week 
after  transplantation”.  12 participants had DGF in the placebo group and 10 in the 
HA group. This equated to 66.7% in placebo and 52.6% in HA. The 14% difference 
(95% CI; -17.2 – 45.3) was not statistically significant (p=0.38). 
 
There were the same numbers of participants who required dialysis in each group (4), 
which equalled 22.2% in placebo group and 21.1% in HA group.  
 
The proportion of participants who had a functioning renal transplant at day 7 was 
also calculated. The day of function  was  defined  using  the  criteria  “dialysis-free and 
>10%  decrease  in  creatinine  compared  to  previous  day”.  There  was  no  statistical 
difference between the groups: 55.6% in placebo and 57.9% in HA group, difference 








3.6.2 30 day and 90 day follow-up 
Table 3- 10 Follow-up results 
 




Number of participants dependent on dialysis 2 (11) 1 (5) 
Evidence of rejection at day 30 1(6) 2 (11) 
 
90-day follow-up   
Number without primary function 2 (11) 1 (5) 
Evidence of rejection at day 90 1(6) 2 (11) 
 
There was no significant difference in either mean or median creatinine values 
between the groups on day 30 or day 90.  
 
At day 30, median creatinine (figure 3- 23) in the placebo group was 120 (103-197) 
and 138 in the HA group (118- 207). At day 90, median creatinine was 116 (90- 151) 

























Figure 3- 23 Comparison of median creatinine from day 30 and day 90 
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On day 30 and on day 90, the difference in mean creatinine between treatment 
groups was also not significant: day 30 was -23.4: placebo (178.6) and HA (202.0), 













4.1 HOT Study conclusion 
Summary of key findings 
The principle aim of the HOT (Heme Oxygenase-1 in renal Transplantation) study 
was to determine if pre-treatment of recipients of deceased donor renal transplants 
with heme arginate (HA) was feasible and safe. The primary outcome was to 
investigate if HA could upregulate heme-oxygenase 1 (HO-1) in recipient 
macrophages and this was achieved safely and effectively. The secondary outcomes 
explored the effect of HA on renal tissue structure and HO-1 expression, urinary 
biomarkers and renal function.  
 
There was no evidence that HA was beneficial to renal structure or function. There 
was a trend to reduced excretion of KIM-1 and NGAL after HA treatment but this 
did not reach significance. Although the trend for reduced DGF rates was not 
statistically significant, the study was not powered to this effect. Given the 
prominence of HO-1 in many different IRI pathologies, the study generates several 
important results. Larger studies are required to investigate if upregulated HO-1 can 
translate to improved functional outcomes. There are very few novel drugs that make 
it to CTIMP trials in renal transplantation and HA presents another option that 
warrants further investigation.  
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4.1.1 HOT study overview 
4.1.1.1 Recruitment 
The study recruited the 40 participants in the pre-stated time frame. It was 
anticipated that the study would recruit about 60% of all admissions for renal 
transplant and out of 76 admissions we recruited 53% (figure 3- 1). There were more 
ineligible participants than expected, reflecting the increasing complexity of 
transplant workload (table 3-1), but an increased departmental workload meant that 
the study met its target (figure 3- 4).  
 
The study had 100% follow-up, which, while impressive, reflects its intensive and 
short-term nature. Two participants declined the second infusion and 14 declined 
biopsies or blood samples but because these participants still gave consent to collect 
clinical data, they remained in the study and so there were no withdrawals (figure 3- 
2 and 3- 3).  
 
The study population was representative of the renal transplant population and 
therefore, the results are applicable to other renal transplant units. The study groups 
were comparable and there was no significant difference in identified characteristics 
(table 3- 2).   
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4.1.1.2 Safety of HA 
HA is a ferric form of heme, which is licensed to treat acute porphyria. The HOT 
study was interested in another function: HO-1 induction. Compared to other 
available hemin preparations, HA is reported to be less thrombotic and vasculotoxic 
(Balla, Balla et al. 2000). This is mainly due to the fact that in HA, hemin is liganded 
to arginine and, as a result, the potentially harmful effects of ferric heme are reduced 
(Tenhunen, Tokola et al. 1987). 
 
This was supported by the HOT study because there were no adverse reactions to or 
unexpected adverse events after HA (table 3- 3). In this study, the adverse event 
profile was similar between groups and HA was well tolerated. This expands current 
knowledge as, prior to this, HA had only been formally tested in healthy male 
volunteers and there was no recorded evidence of use in patients with end stage renal 
disease (ESRD) and immunosuppression.  
 
The HOT study dose regime (3mg kg-1) was chosen because it was within the safe 
licensed dose and is known to be sufficient to induce PBMC HO-1 in vivo and in 
vitro. Healthy volunteer studies found that PBMC HO-1 protein expression peaked at 
24 hours after HA exposure and was declining at 48 hours. Therefore, the second 






4.1.2 Heme-oxygenase 1 upregulation  
As explored in the introduction, HO-1 is induced in response to multiple stimuli 
including hypoxia and ischaemic cytokines so it was anticipated that all participants 
would experience an upregulation in HO-1 after transplantation (Shimizu, Takahashi 
et al. 2000). Heme is a well-known HO-1 inducer. Free heme binds to hemopexin 
and the complex then undergoes endocytosis where the intracellular heme can 
activate HO-1 transcription through Bach1 and Nrf2. The study, therefore, 
scrutinized whether the amount of HO-1 upregulation differed between groups.  
 
4.1.2.1 PBMC population 
In the HOT Study, immunohistology, ELISA and qRT-PCR confirmed PBMC HO-1 
upregulation.  
 
HA treatment increased PBMC HO-1 protein and mRNA significantly more than 
placebo treatment and restates results from the phase I studies (Bharucha, Kulkarni et 
al. 2010, Doberer, Haschemi et al. 2010).  
 
The primary outcome established that HA treatment upregulated HO-1 protein 10 
times greater than placebo at 24 hours (p= <0.0001) (figure 3- 5). This exceeded the 
findings of the healthy volunteer study that reported HO-1 protein expression five 
times baseline at the same time point (Doberer, Haschemi et al. 2010). This may be 
explained by the increased ischaemic insult suffered by our patients compared to 
healthy individuals in a controlled setting. The pattern of HO-1 PBMC protein 
expression was also as expected; there were two discrete peaks after the HA 
infusions with a return to near baseline expression after 24 hours (figures 3- 6, 3- 7).  
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Previous research found PBMC HO-1 mRNA was elevated in acute inflammatory 
illnesses, which was given as evidence of HO-1 as a mechanism for limiting 
excessive cell or tissue injury in the presence of oxidative stress (Yachie, Toma et al. 
2003). The HOT study supported that conclusion because even the placebo group 
had a 1-fold increase in HO-1 mRNA at 24 hours post-infusion reflecting the 
oxidative stress of surgery (figure 3- 8). HA had an additive effect and resulted in a 
significant 2-fold upregulation of HO-1 mRNA (p=0.02). These results echo the 
findings from the previous healthy volunteer study, which reported a 2-fold increase 
in PBMC HO-1 mRNA 24 hours after HA, which had reduced to 1.5-fold increase at 
48 hours. In the HOT study, the pattern of mRNA upregulation was not as predicted 
because although there was a clear peak at 24 hours, this was not significant after the 
second infusion (figure 3- 9 and 3- 10). This anomaly may be due to the 2-ΔΔCT 
method used because all samples were referenced to baseline (day 0). It may be more 
appropriate to normalise day 3 results to day 2 to elicit any evidence of upregulation.  
 
There have been many methods described to detect differences in HO-1 expression 
or upregulation including direct measures such as leucocyte protein concentration 
and indirect surrogate measures, for example plasma bilirubin, expired carbon 
monoxide (CO), nasal swab mRNA or urinary HO-1. Bharucha et al found increased 
HO-1 protein in plasma and increased HO-1 activity in healthy volunteers after HA 
infusion but HO-1 upregulation in PBMCs was considered a better measure of the 
cytoprotective action and the HOT study adopted this method as suggested by 
Doberer (Doberer, Haschemi et al. 2010).  
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The urinary method used to evaluate bioflavinoids as potential HO-1 upregulators 
has not been validated or replicated and would not have been suitable for renal 
transplant recipients (Shoskes, Lapierre et al. 2005). In the healthy volunteer study 
that investigated sulforaphane as a potential HO-1 upregulator, the amount of HO-1 
mRNA in nasal aspirate was used as a primary endpoint. However, although this 
non-invasive technique is attractive, the specificity and sensitivity is unknown and 
the relationship between nasal mRNA and cellular physiology is unclear (Riedl, 





4.1.2.2 Renal samples 
4.1.2.2.1 Renal macrophages 
The HOT study was the first clinical study to examine the transplanted kidney for 
HO-1 upregulation by qRT-PCR and immunohistochemistry (IHC) (figure 3- 11).  
 
There were similar numbers of macrophages in back table tissue regardless of 
treatment group (p=0.956) (figure 3- 12). As expected after an ischaemic insult, there 
was an increase in the number of macrophages in the day 5 tissue compared to back 
table. The increase is due an influx of recipient macrophages infiltrating the graft. 
Human data is lacking but this has been shown in animal models of renal IRI (Jo, 
Sung et al. 2006). When the role of macrophages in renal transplant studies was 
reviewed in Vascular Cell the authors described the infiltration of the graft by 
phenotypically distinct macrophages in different IRI phases (Jiang, Tian et al. 2014). 
 
At day 5, there were more interstitial macrophages detected in the HA treatment 
group although this was not significant (p=0.13) (figure 3- 12).  
 
There were no HO-1 positive CD68 cells in the back table biopsy samples and 
therefore the significant population detected in all the day 5 samples were HO-1 
expressing, recipient macrophages infiltrating the graft. In agreement with previous 
animal work, there were significantly more HO-1 positive CD68 cells in the HA 
treated group (p=0.012) (figure 3- 13).  
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4.1.2.2.2 Renal tissue 
The HOT study demonstrated that HA treatment significantly increased the 
concentration of HO-1 protein in renal tissue as measured by IHC (p=0.017) (figure 
3- 14 and 3- 15). However, the differences between the groups were small and 
closely clustered around 0 with the majority of samples having no difference in HO-
1 expression between back table and day 5 (table 3- 4). There was no evidence that 
HA resulted in an upregulation of HO-1 mRNA in renal tissue either as comparing 
the median difference (p=0.45) (figure 3- 16) or comparison of proportions test (p= 
0.994) (table 3- 5).  
 
These findings can be explained. Renal tissue sampling was problematic. The initial 
plan was to analyse HO-1 protein in renal tissue by Western Blot but the samples 
were too small for accurate and reproducible protein analysis.  
 
There are a number of possible explanations why the renal tissue results were not as 
convincing as expected:  
 
1. There was a real, significant upregulation of renal HO-1 after HA but it was not 
captured by the HOT study analysis because the number of paired renal samples 
was too small (only 22 out of 37 potential samples). Eight participants with 
primary function declined the day 5 biopsy. An additional four participants were 
not considered well enough or had contraindications for renal biopsy. This 
relatively low take-up was not unexpected because a renal biopsy has recognised 
risks. The responses will help to plan the follow-on study, which may not include 
a day 5 biopsy. 
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2. There was a real, significant upregulation of HO-1 after HA but it was not seen 
because the sample quality was too poor. Despite expert examination prior to 
freezing, the subtype of renal tissue was not standard or guaranteed. HO-1 is 
preferentially upregulated in tubular cells, specifically the outer stripe of the 
medulla (OSOM), but the amount of this tissue varied in each sample.  
The tissue samples were also small and this impacted on preservation and 
analysis quality. Although there was ethical approval for two renal biopsies at 
back table and two on day 5, the experience and preferences of the surgeons and 
radiologists taking the biopsies affected the sample size and quality. The qRT-
PCR analysis of the renal tissue occasionally generated CT values at the extent of 
the machine capability, which may have had a negative influence on reliability.  
 
3. HO-1 mRNA upregulation occurred but the timing of the protocol biopsy missed 
it. mRNA is a more transient marker than protein and the half-life of HO-1 
mRNA in in vitro renal cells treated by hemin is only around four hours (Hill-
Kapturczak, Sikorski et al. 2003). Animal models show that, following heme 
stimulation, renal HO-1 mRNA expression is first measurable at six hours and 
has returned to baseline by 24 hours (Shimizu, Takahashi et al. 2000). HA also 
only has a half-life of ten hours. The HOT study attempted to extend the effect of 
HA by repeating the dose on day 2 but this was untested and may still be too low.  
 
The timing of the biopsy also varied between subjects because the biopsy service 
was not available at the weekend. This led to 7/25 biopsies being performed on 
day 6-post infusion and this may have negatively impacted on the results.  
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In addition it should be highlighted that the renal tissue protein and mRNA results 
may be of limited value because the predominant source of HO-1 positivity in human 
renal tissue comes from infiltrating macrophages (Gueler, Park et al. 2007). It was 
confirmed in 4.2.2.2.1 that HA had a positive effect on renal macrophage HO-1 
expression.  
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4.1.3 HA effect on histological tissue 
In contrast to experimental models, there was no evidence that HA had a positive 
effect on the histological health of the kidney at day 5 (p=0.95) (Ferenbach, 
Nkejabega et al. 2011)(table 3- 8 and figures 3- 17 and 3- 18). The first two reasons 
quoted in 4.1.2.2.2 are also valid to explain this finding.  
 
Crucially the clinical study results do not replicate animal models because human 
transplant is more complex involving donor and retrieval factors, 
immunosuppression and additional disease processes. The HOT study samples were 
also potentially more complicated than those analysed in preclinical studies because 
the later time point also captures features of resolution and repair in addition to the 
original injury.  
 
The differences in injury scores between paired samples (back table biopsy and day 5 
biopsy) were also compared (tables 3- 6, 3- 7 and 3- 8), and although HA was more 
likely than the placebo group to result in an improvement in injury scores, the sample 
was too small for formal analysis (p=0.63). A larger sample size is required to 




4.1.4 HA effect on urinary biomarkers 
Serum creatinine is an unreliable indicator of acute kidney injury and does not reflect 
the degree of damage until it plateaus, which may be several days post-operatively 
(Parikh, Jani et al. 2006). Creatinine kinetics varies between individuals and may be 
influenced by multiple non-renal factors, which confuses the interpretation of renal 
function. Clinicians are still looking for a better assay that would be prognostic for 
DGF, allowing earlier and targeted management (Hall, Yarlagadda et al. 2010). A 
biomarker is a biologic characteristic that is measured and evaluated objectively as 
an indicator of normal biologic processes, pathological processes or responses to an 
intervention (Coca and Parikh 2008). If proven, analysis of selective biomarkers 
could alter patient management and serve as outcomes for transplant drug 
development (Hall, Doshi et al. 2012). 
 
The HOT study explored whether HA had an impact on two urinary biomarkers: 
neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury marker-1 
(KIM-1). These biomarkers were chosen because they have been shown to be 
applicable in transplantation and have different pathways of production to capture 
different mechanisms of injury. Commercial, validated assays are also available. 
 
There were no statistical significant differences in maximum or median NGAL or 
KIM-1 between groups, both using the raw data and when allowing for differences in 
urine concentration (figure 3- 19 and 3- 20). The maximum NGAL and KIM-1 levels 
were lower in HA group indicating reduced renal injury but not significantly so 
(table 3- 9).   
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The analysis of biomarkers was limited in some patients by negligible urine 
production. For many patients with DGF, there was no urine available to test and this 
therefore may have skewed results. As mentioned previously, urinary biomarker 
results were not taken into account when calculating the study size and therefore it 
may be underpowered to see a difference in these samples. AUC analysis was also 
not able to distinguish between participants with DGF in this small sample (figure 3- 
21). 
 
Urinary biomarkers, including NGAL and KIM-1, are proteins that are released from 
damaged kidney cells into the urine and therefore, increase after injury. They peak 
earlier than creatinine and have been considered in many different renal injury 
scenarios as potentially more timely, accurate and less invasive predictors of injury 
(Hall, Doshi et al. 2012). However, a consensus has yet to be reached on the 
usefulness of urinary biomarkers and research continues. They are not currently part 
of routine UK clinical practice.  
 
NGAL is one of the most promising markers. It is expressed at low levels in normal 
kidneys but is upregulated in damaged tubules, from which it escapes into the urine 
(Mishra, Dent et al. 2005). In addition to its role as a marker of disease, NGAL is 
also recognised as an iron-transporting protein and has been investigated as therapy 
for acute renal injury in mice (Mishra, Mori et al. 2004). It may also be involved in 
HO-1 upregulation because, while NGAL offers protection in acute kidney injury, 
this protective effect is lost when HO-1 is inhibited (Mori, Lee et al. 2005).  
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One group found that they were able to accurately predict the need for dialysis within 
the first week and also the 1-year graft function from the level of NGAL in a 
recipient’s  urine  collected  on  the  first  day  post-transplant using an adult study 
population four times larger than the HOT study (Hall, Yarlagadda et al. 2010, Hall, 
Doshi et al. 2012). Another group found similar results in Finnish deceased donor 
recipients in the first few weeks supporting the hypothesis although this was not 
supported in longer-term follow-up (Hollmen, Kyllonen et al. 2011). Other studies 
were limited by small sample sizes of mixed deceased and living donors (Mishra, Ma 
et al. 2006, Parikh, Jani et al. 2006). The recent review by Ronco advocates the use 
of routine NGAL testing in a variety of clinical settings including early renal 
transplant but larger studies are required to corroborate sensitivity and specificity 
(Ronco, Legrand et al. 2014).  
 
KIM-1 is a transmembrane protein, which is undetectable in normal kidneys and 
overexpressed in proximal tubular cells during ischaemic and nephrotoxic acute 
kidney injury making it an ideal biomarker (Coca and Parikh 2008, Bonventre and 
Yang 2010). The level of KIM-1 correlates with kidney function post-transplant 
(Malyszko, Koc-Zorawska et al. 2010). One group found that urinary KIM-1 was an 
independent predictor of graft loss in renal transplantation although this study took 
place in an outpatient setting and therefore could not comment on the value of KIM-
1 at detecting DGF in the first week post-transplant (van Timmeren, Vaidya et al. 
2007). There is also evidence that urinary KIM-1 levels from recipients under 
investigation for acute rejection correlate to declining renal graft function although 
the same was not true of NGAL (Szeto, Kwan et al. 2010).  
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As evidence that further clarification is needed, the Hall study that supported NGAL 
found that KIM-1 was not of value at predicting renal recovery (Hall, Yarlagadda et 
al. 2010).   
 
The HOT study was too small to make assumptions about the value of these two 
urinary biomarkers after transplant and a global conclusion has yet to be reached 
about the use of biomarkers as predictors of DGF. The HOT study chose two well 
recognised biomarkers but there are many more under investigation such as IL-8 (a 
proinflammatory cytokine) and clusterin (a protein associated with clearance after 
apoptosis) (Pianta, Peake et al. 2014). Each biomarker may offer different predictive 
insights and, as more biomarkers are identified, tested and validated, it may become 
apparent that the best solution is a panel of biomarkers that could stratify future 
function and aid clinician decision-making. If biomarkers are shown to provide 
specific and sensitive prognostic information, they could guide treatment planning 
and improve patient information for better clinical care. NGAL and KIM-1 are of 





4.1.5 HA effect on function  
4.1.5.1 Delayed graft function (DGF) 
Delayed graft function is clinically important and there is evidence that while one 
episode of dialysis post-transplant has no effect on graft survival, patients requiring 
more than one episode of dialysis have inferior clinical outcomes (Yarlagadda, Coca 
et al. 2009, Jayaram, Kommareddi et al. 2012). DGF occurs in between 20 to 35% of 
recipients and the mechanisms are not fully understood (Siedlecki, Irish et al. 2011). 
With improved strategies to prevent acute rejection, DGF is the most important 
factor impacting on long-term allograft survival (Serur, Saal et al. 2011). In the HOT 
study, there were fewer cases of delayed graft function after HA treatment but this 
was not statistically significant (p=0.38). This may be because the study was not 
designed to compare functional outcomes and the numbers analysed were not large 
enough to detect the small difference in function. However, the DGF analysis was 
performed due to its relevance for clinical implications.  
 
A variety of clinical definitions exist for DGF; Yarlagadda identified 18 
(Yarlagadda, Coca et al. 2008). A clinical trial is currently recruiting in Korea to 
compare various definitions of DGF and to find the definition that best predicts graft 
function and survival (NCT02080117 clinicaltrials.gov).  
 
In the HOT study, DGF was defined as an increased or stable serum creatinine, or a 
decrease of less than 10% per day in three consecutive days in the first week after 
transplantation:  the  “functional”  definition  as  advocated  by  Moore (Moore, Shabir et 
al. 2010).  
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It has been acknowledged that the dialysis-based definition is subjective and may 
represent clinician choice rather than true graft function (Sharif and Borrows 2013). 
Moore et al compared these two DGF methods and demonstrated that functional 
DGF but not dialysis requirement was associated independently with subsequent 
death-censored transplant failure. The functional method is also easier to accomplish 
and validate for large or retrospective studies, as case note examination is not 
required. For completeness, the need for dialysis was also compared and it was the 
same between groups.  
 
It is recognised that regardless of definition, DGF is difficult to predict and trials 
attempting to foretell DGF as an outcome measure have had limited success as 
reviewed by Sharif (Sharif and Borrows 2013). Dopamine remains one of the only 
agents to have proven success in reducing DGF when given to donors (Schnuelle, 
Gottmann et al. 2009). Neither recipient treatment with erythropoietin (Martinez, 
Kamar et al. 2010, Sureshkumar, Hussain et al. 2012) nor pre-treatment of deceased 
donors with steroids (Kainz, Wilflingseder et al. 2010) or N-acetylcysteine (Orban, 
Quintard et al. 2014) saw a difference in DGF despite evidence that the drugs 
protected kidneys in preclinical studies.  
 
4.1.5.2 Day 30 and day 90 follow-up 
There was no difference in function at follow-up and in fact the placebo group had a 
lower mean and median creatinine but there was no statistically significant difference 
(figure 3- 23). The numbers of participants with rejection were too small to compare 
but there was no evidence that HA increased the risk of rejection (table 3- 10). 
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4.1.6 Assessment of genotype impact in HOT study 
The GT polymorphism that modulates HO-1 gene transcription varies in size and 
allows  individuals  to  be  defined  as  short  allele  “S”  (<25/  27/  28  repeats) or long 
allele    “L”(>  25/  27/  28)  responders.  The  longer  GT  repeat  corresponds  to  reduced  
transcription activity and increased risk for a variety of diseases (Chen, Lin et al. 
2002, Exner, Minar et al. 2004). Initial studies showed that S/S or S/L grafts had 
better outcomes after renal transplantation (Exner, Bohmig et al. 2004). However, as 
research interest increased, the significance of HO-1 genotype appeared to decrease 
and  Exner  et  al’s  initial  results  have  not  been  replicated.  Separate  studies  from  
Belfast (Courtney, McNamee et al. 2007), Finland (Turpeinen, Kyllonen et al. 2007) 
and Greece (Katana, Skoura et al. 2010) found that neither donor nor recipient 
genotype significantly influenced graft or recipient survival. A retrospective study 
looking at a variety of inflammation genotypes including HO-1 could not find a link 
between HO-1 genotype and DGF rates after deceased donor kidney transplantation 
(Israni, Li et al. 2008).  
 
Doberer et al examined the impact of genotype in their healthy volunteer study and 
found that GTn length polymorphism had no effect on the extent of HO-1 induction 
in PBMCs. In fact, they found the opposite, with HO-1 mRNA greater in those 
homozygous for long allele (L/L) (Doberer, Haschemi et al. 2010). In the HOT 
study, all participants were assigned to one of three genotype groups: S/S, L/L, S/L 
and the distribution corresponded with previously quoted prevalence patterns 
(Doberer, Haschemi et al. 2010). There were no participants with S/S genotype in the 
HA group so further subgroup analysis was not possible (table 3-2).  
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For interest, S/L vs. L/L analysis was performed and the difference in PBMC HO-1 
protein upregulation was not significant (p=0.59).  
 
Doberer suggested that different PBMC subtypes may respond to HA differently and 
that further PBMC subpopulation analysis may be required before the genotype 
hypothesis is dismissed completely (Doberer, Haschemi et al. 2010). This conclusion 
could equally apply to the HOT study.  
 
In a review of HO-1 genotype in renal injury, Courtney et al hypothesised that there 
are other gene variants that confer protection in renal transplantation, which may 
compensate for a genetic predisposition towards lower HO-1 production in L/L 
individuals. This would ensure that even if the HO-1 genotype did negatively alter 
the cellular response to injury, it would be masked clinically (Courtney and Maxwell 
2008). This seems feasible given the strong importance of HO-1 as evident in the 
case of the HO-1 deficient individual and HO-1 -/- animals (Kawashima, Oda et al. 





4.1.7 Generalizability and limitations of HOT study 
Despite clear evidence that HA upregulated HO-1, it did not translate into structural 
or functional evidence of renal cytoprotection seen in many animal models and 
clinical studies (Katori, Busuttil et al. 2002, Tullius, Nieminen-Kelha et al. 2002, 
Blydt-Hansen, Katori et al. 2003, Lemos, Ijzermans et al. 2003, Wagner, Cadetg et 
al. 2003, Ollinger, Kogler et al. 2008, Ferenbach, Nkejabega et al. 2011).  
 
The HOT study was a single-blind single-centre randomized trial but because of the 
blinding of surgeons, nephrologists and nurses in charge of the recipients and the 
blinding of data management and sample analysis, it seems unlikely that this would 
have introduced bias to the laboratory samples. Also given the clear definition of 
DGF in the HOT study, it is also unlikely that the treatment had any influence on 
clinical outcome. The study adhered to CONSORT guidelines for randomised 
control trials and therefore the results should provide high quality evidence. 
 
The study population was representative and this should ensure that our conclusions 
can be safely and effectively translated to other renal transplant units. 
 
There are a few possible explanations why HO-1 upregulation did not confer 
protection: 
 
1. The sample size was too small to detect a difference in histological injury or rates 
of delayed graft function between the groups. The study was not powered to 
these endpoints so this was not unexpected and larger studies are planned.  
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There is also the challenge that the majority of cadaveric renal transplants have 
primary function, thus cannot get further clinical benefit from HA. This will 
increase the numbers required in any study aiming for a definitive clinical 
outcome. 
 
2. It may be that two doses of HA were insufficient to give protection and 
potentially more HA is required to maximise and sustain the effect on 
macrophages and renal tissue. HO-1 expression increases with increasing HA 
doses (Doberer, Haschemi et al. 2010) and the license for porphyria permits four 
doses. The proposed alterations to the follow-up study are explored in 4.3.1. 
 
The timing of the HA dose also varied and there was a wide variation in infusion-
to-graft-reperfusion time between participants although the mean and median 
times were not statistically significant between groups. It is not known whether 
there is an optimal infusion time for maximal HO-1 effect in graft tissue. Further 
studies will hope to evaluate the benefits of a higher dose or longer exposure.  
 
3. It is possible that the structural and functional results are genuine and HA has 
other effects in IRI that prevents the HO-1 upregulation having its anticipated 
effect. While the study showed an increase in the known anti-oxidative and 
vasodilatory agent HO-1, it did not measure biological surrogate markers of 
oxidative stress or haemodynamic parameters to confirm the HO-1 effect. 
Therefore, it may be that the upregulated HO-1 did not have its expected, proven 
and beneficial actions in this trial. This remains to be explored.  
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4. The HOT study was interested in HO-1 induction but there are reports that basal 
HO-1 activity is more important for antioxidant action and this has not been fully 
explored (Tsuchihashi, Livhits et al. 2006). The HOT study did not categorise 
participants into subgroups based on basal HO-1 expression but this may be 
appropriate for further studies. There was a wide range of baseline HO-1 
expression (as seen in raw numbers in figure 3- 6) and this variation may be 
worth exploring.  
 
5. It has also been proposed that the protective response of HO-1 may be limited 
and susceptible to being overwhelmed. It may be that once a level of injury has 
been reached, additional HO-1 induction cannot prevent further damage 
(Tsuchihashi, Livhits et al. 2006). Clinical renal transplantation delivers sizable, 
diverse insults to the kidney, which are not fully modelled in animal 
experimentation, and may explain why preclinical findings do not equate to 
human studies.  
 
6. Further research may show that HO-1 upregulation does not have the same 
protective effect on all grafts. Pre-clinical studies showed that HO-1 upregulation 
by HA gives maximal protection in older mice but had less effect in younger 
animals (Ferenbach, Nkejabega et al. 2011).    It  may  be  that  the  “better”  organs  
experience very little benefit from HO-1 upregulation because they are already 
optimal  but  the  poorer  “marginal”  kidneys  have  either  more  to  gain  or  more  
capacity for improve.  
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The HOT study did not have sufficient numbers of ECD organs (2 in placebo and 
4 in HA) to analyse separately but larger studies, which should allow for 
subgroup analysis, will try to answer this question. If this is found to be the case 
then HA may be offered to a select group of recipients only and form part of a 
targeted treatment regime.   
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4.2 Future considerations 
 
4.2.1 Preconditioning as a method for preventing renal IRI  
The technique being tested in the HOT study is known as preconditioning, which can 
be either ischaemic (IPC) or pharmacological (Selzner, Boehnert et al. 2012). 
Preconditioning is defined as a situation when an animal is exposed to a stressor or 
stimulus at a non-toxic concentration in order to prepare it for a later encounter with 
similar larger stressors (heme in the case of the HOT study) (Bonventre 2002). 
Several models have shown that hemin pre-treatment is protective in acute injury 
including cerebral, cardiac and hepatic as reviewed by Lu (Lu, Chen-Roetling et al. 
2014) but until now, this has not translated to human studies.  
 
IPC was originally described in 1986 when it was found that a brief episode of non-
lethal cardiac ischaemia protected canine cardiac muscle from ensuing prolonged 
cardiac ischaemia (Murry, Jennings et al. 1986). Cochrane et al also confirmed the 
phenomenon in renal injury when they found that the kidneys of rats that had 
received a small ischaemic stimulus prior to 45 minutes of ischaemia had improved 
function and less histological injury than the control group with no preconditioning 
(Cochrane, Williams et al. 1999). Research was furthered by the recognition that the 
IPC event need not occur directly to the organ of interest. Wever et al found that an 
ischaemic  event  to  an  animal’s  limb  conferred  the  same  preconditioning protection 
against IRI as a direct ischaemic event to the kidney (Wever, Masereeuw et al. 
2013). This is known as remote ischaemic preconditioning (RIPC).  
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Despite the known beneficial effects of IPC and RIPC in many disease pathologies, 
clinical trial results have been mixed (Szwarc, Soullier et al. 2007, Huang, Shan et al. 
2009). While initial results from clinical trials of IPC in liver transplant were positive 
(Amador, Grande et al. 2007) another group raised the issue of an “IPC  paradox”;;  
where IPC did more harm than good. (Koneru, Fisher et al. 2005, Koneru, Shareef et 
al. 2007). Although the initial randomised controlled trial (RCT) by Koneru et al in 
2005 found no difference in recipient function or graft injury after a 5 minute period 
of liver ischaemia prior to liver donation in 62 donors, their follow-up study of 101 
donors found that IPC prior to liver transplant actually increased IRI.  
 
Three recent RCTs from Asia have investigated RIPC in renal transplant. Chen et al 
found no benefit in renal function at 72 hours after pre-transplant RIPC to either 
donor or recipient although accepted that study numbers were small (Chen, Zheng et 
al. 2013). In contrast, Kim et al detected an improvement in donor renal function at 
24 hours after recipient RIPC treatment but this result was not sustained long term 
(Kim, Lee et al. 2014). However both of these trials were in living donors and it was 
acknowledged that the majority of the grafts were expected to have primary function. 
It was therefore suggested that either the sample size was increased or the studies 
were repeated in deceased donors at higher risk of IRI. This hypothesis was 
supported by a recent trial who found that when recipients of deceased donor renal 
grafts received an ischaemic stimulus, in the form of a brief external iliac artery 
occlusion at time of implantation, there was an improvement in creatinine and eGFR 
during the first two weeks post transplant. The improvement was not sustained 
beyond this but suggests potential (Wu, Feng et al. 2014). 
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Potential reasons behind the reported IPC paradox were explored in a review article 
by McCafferty et al who highlighted the problems of extrapolating the results from 
animal models to human studies (McCafferty, Forbes et al. 2014). They highlighted 
the differences in the study environments comparing the use of juvenile, male, inbred 
animals housed in controlled conditions with patients with multiple co-morbidities 
and medications recruited to clinical studies. Diabetes, hypercholesterolaemia, 
hypertension and obesity have all been shown to have an impact on preconditioning 
strategies and some medications act as pharmacological preconditioning agents, 
which further muddies the data. The best human conditioning protocol is also 
unknown and larger clinical trials are required to examine this potential area of 
interest. There is a multi-centre RCT led by University College London, which aims 
to recruit 400 living-donor transplant patients to look at the impact of RIPC on renal 
function post-transplant and the results are eagerly awaited (protocol 
ISRCTN30083294 RIPC in renal transplantation). 
 
The results from the HOT study support HA as an alternative to other renal 
transplant pharmacological conditioning strategies that have not fulfilled their 
potential when translated to clinical studies. Despite giving protection in animal 
models, erythropoietin has not been shown to be cytoprotective in humans. A study 
comparing high-dose recombinant human erythropoietin to placebo found that, while 
adverse events were similar, there was no evidence of functional or histological 
improvements at short (six weeks) and long (12 months) term follow-up (Hafer, 
Becker et al. 2012). The outcome was the same in the Neo-PDGF trial that looked at 
high does of epoetin beta (Martinez, Kamar et al. 2010). Later trials similarly found 
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no evidence that erythropoietin improved function but also raised safety concerns 
(Aydin, Mallat et al. 2012). Similarly N-acetylcysteine did not improve DGF rates 
when given to over 100 deceased donors despite good suggestive data from animal 




4.2.2 Other potential methods for HO-1 upregulation  
 
The time delay from dosing to upregulation of defensive mechanisms may limit the 
use of HA in acute ischaemic scenarios such as MI or stroke, but this makes it 
suitable for use in transplantation when delay is inevitable and strategic. However, 
HA is expensive and, as it can only be given intravenously, potentially difficult to 
give effectively. Despite this, it remains a better option than many of the harmful 
solutions used in preclinical studies but research continues into other options.  
 
The same group that investigated the effect of hemin on healthy volunteers looked at 
other potential HO-1 upregulators. They gave healthy volunteers seven days of oral 
medications including various combinations of aspirin, statin and the sodium salt of 
R-alpha-lipoic acid to investigate if they could do the same job as expensive 
intravenous preparations (Bharucha, Choi et al. 2014). The group found that none of 
the medications had an effect on HO-1 protein concentration or venous monocyte 
HO-1 activity at two or seven day follow-up.  
 
Despite evidence that curcumin induced HO-1 in human monocytes in culture (Hsu, 
Chu et al. 2008), healthy volunteer studies found that oral curcumin had low 
bioavailability and did not influence HO-1 mRNA or protein in PBMCs (Klickovic, 
Doberer et al. 2014). 
 
IPC also upregulates HO-1 in animal renal tissue (Shokeir, Hussein et al. 2014) and 
the RCT currently recruiting to investigate the impact of RIPC on renal function after 
transplant should offer insights into protein expression.  
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4.2.3 Treatment of deceased donors 
Despite its undeniable position as a life-changing opportunity to many ESRD 
patients, deceased donor transplantation remains challenging. Recipients of organs 
from unrelated living donors with poor HLA matching still have better graft function 
and survival compared to those who receive organs from well-matched deceased 
donors (Terasaki, Cecka et al. 1995). 
 
Donor treatment remains a relatively underdeveloped area of clinical science, 
especially when one considers the substantial potential to intervene and improve 
organ function. It can be argued that given our knowledge of IRI, treatment of a 
potential organ donor offers the best chance to ameliorate the harmful downstream 
effects. Animal studies confirm that donor treatment prior to organ retrieval gives 
positive outcomes but attempts to transfer all but the most straightforward drugs to 
the clinical setting poses complex ethical issues (Kotsch, Ulrich et al. 2008). The 
recent publication of a randomised trial of French deceased donors treated with N-
acetylecysteine may offer a model for future deceased donor research (Orban, 
Quintard et al. 2014). IPC appears to represent a lower-risk option and there are trials 
currently recruiting to investigate the effect of donor IPC on subsequent graft 
function (Feng 2010).  
 
Pre-treatment of rat renal donors at onset of brain death with either steroids or P-
selectin glycoprotein ligand (PSGL), a blocker of cell adhesion, improved recipient 
survival and reduced acute rejection episodes. It was hypothesised that it protected 
against IRI because there were fewer inflammatory markers in treated animals 
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(Pratschke, Kofla et al. 2001). Gasser et al found similar results after PSGL treatment 
and also showed improved function at day 200 (Gasser, Waaga et al. 2002). Reutzel-
Selke et al expanded this concept and pre-treated rat donors with four 
immunosuppressive drugs commonly prescribed to human recipient treatment 
including steroid, MMF, tacrolimus and everolimus. They found that pre-treating 
with prednisolone or tacrolimus reduced the cytokine and cellular inflammatory 
response and as a result, significantly improved graft function and structure 
compared to control. MMF and everolimus also had benefits but did not reach 
significance (Reutzel-Selke, Zschockelt et al. 2003). Steroid treatment of donors is 
now routine after a randomised trial showed that it reduced inflammation in organs 
after transplant (Kotsch, Ulrich et al. 2008, Feng 2010). 
 
Pre-treatment of organ donors with a variety of catecholamines reduced renal 
inflammatory cell infiltrates and improved renal function. The effect was maximal 
with dopamine (Gottmann, Brinkkoetter et al. 2006). When this was expanded to a 
randomised multi-centre clinical trial, dopamine pre-treatment reduced the need for 
recipient dialysis and has changed clinical practice (Schnuelle, Gottmann et al. 
2009). The protective effect of dopamine is thought, in part, to be mediated through 
HO-1 induction (Schnuelle, Yard et al. 2004). 
 
Donor pre-treatment with desmopressin is also associated with improved graft 
survival and this effect was enhanced when combined with dopamine (Benck, 
Gottmann et al. 2011). This is now widely used in donor management (McKeown, 
Bonser et al. 2012). 
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In pre-clinical studies, pre-treatment of brain dead donors with cobalt protoporphyrin 
led to an improvement in rat renal graft function and survival when compared to HO-
1 blocker zinc protoporphyrin (Tullius, Nieminen-Kelha et al. 2002, Kotsch, 
Francuski et al. 2006). However the group concluded that while HO-1 induction in 
donors by pharmacological means was beneficial, there are limited compounds 
suitable for human use. HA may therefore offer a safe, effective alternative for 
preconditioning treatment of organ donors. However, a clinical trial of HA in donors 
is a long way off. While donor treatment with dopamine, desmopressin and steroids 
is now common, many molecular pathways of IRI including HO-1 remain 
unexplored and have not percolated through to human investigation (Feng 2010).  
 
In their article Abt et al (Abt, Marsh et al. 2013) highlight the sparse number of 
donor intervention trials and discuss the ethical issues limiting clinical research. 
While they focus on the USA, many of their points are equally valid to the UK. 
Approval is difficult as, once a donor has been identified, the consent process no 
longer applies to only the donors but also to any family members, waiting-list 
candidates, multiple retrieval teams and organ recipients. By its very nature, clinical 
research also has the potential to cause harm and this risk may be counter to the 
wishes of the donor and family. The historical deceased donor trials used proxy 
consent but this does not address recipient consent, which poses further ethical 
issues. Given the complex nature of transplant, doctors treating the donor are usually 
some distance away and not linked to the multiple recipient care teams so that 
information about donor treatment cannot be quickly and clearly disseminated. These 
barriers mean that innovation is stifled and clinical trials for deceased donation are 
often abandoned reducing potential sources of knowledge.  
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4.2.4 Treatment of organs  
As discussed in 4.2.3, ethical and legal rules mean few interventions have been 
trialled in deceased donors. The same rules do not apply to isolated, retrieved organs 
and this offers a potential window of intervention. 
 
One example of such an intervention is the development of machine perfusion. 
Machine perfusion has been shown to be beneficial to early kidney function and 
longer-term graft survival compared to conventional cold storage methods and is 
now in routine use (Moers, Smits et al. 2009).  
 
A novel research focus is the development of organ perfusion fluids containing 
protective compounds including carbon monoxide (CO). A CO-containing solution 
reduced proinflammatory mediators post renal transplant and improved kidney 
function in an animal model. Similar biochemical changes were seen in human 
organs that were not fit for transplant and this should be expanded (Ozaki, Yoshida 
et al. 2012). However, there is reluctance to pursue this avenue because once the 
organ is in chilled isolation and not actively metabolising, it could be too late to 
impact on the preceding ischaemic inflammatory processes. This may explain why 






4.3 What next? 
The HOT study used renal transplant as a model of IRI and it is hoped that these 
findings can be extrapolated to other pathologies where upregulation of HO-1 is 
known to be protective. The HOT study results have been used as preliminary data 
for a sample size calculation for a follow-on study in our unit to investigate the use 
of HA to prevent acute kidney injury after cardiac surgery. 
 
4.3.1 Expanding the HOT study  
The primary aim of the HOT study was to investigate the safety and efficacy of HO-
1 induction by HA. Although there was a trend to protection against DGF, the study 
was not powered to this effect and therefore larger studies are required to see if 
upregulated HO-1 in PBMCs and renal tissue translates to the improved functional 
outcomes seen in animal work (Gueler, Park et al. 2007, Ferenbach, Nkejabega et al. 
2011).  
 
4.3.1.1 Plan for HOT2  
The sample size calculation for HOT2 has suggested that in order to detect a 
difference in clinical outcome, namely DGF, 350 - 400 participants are required. In  
the HOT study, 82% of all recipients of single kidney, deceased donor transplants 
met eligibility criteria and of them, 83% consented to the trial. Last year, there were 
100 renal transplants performed at Edinburgh Royal Infirmary (ERI) and therefore it 
would take at least 70 months to recruit 400 patients at ERI alone. One potential 
solution is to recruit from other centres too. The two nearest transplant units, 
Glasgow and Newcastle, have been approached and would be interested in principle.  
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The following points highlight the necessary amendments to the HOT protocol to 
allow effective expansion: 
 
The primary outcome for HOT2 will be whether HA has an effect on the rate of 
DGF. This endpoint can be recorded retrospectively from online blood results. This 
will ensure that HOT2 is less invasive and demanding of researcher and participant.  
 
The main hurdle to HOT expansion is manpower. In order to ensure that the HOT 
protocol was followed, the CI was responsible for all aspects of the seven-day study. 
The HOT study was labour intensive and it would be impossible to simply expand 
the same trial protocol to recruit 400 patients across more than one site. In the HOT 
study, the participant was approached, consented, randomised and given the HA 
infusion as soon as they arrived to ensure the recipient macrophages received 
maximum HA exposure prior to transplant. However, such a set-up would not be 
possible unless there was a designated Principle Investigator (PI) always on-call at 
each site to consent and give the HA.  
 
One possible solution to recruitment would be to approach all eligible renal 
transplant waiting list patients with information about HOT2 at the start of the trial 
and they would sign a preliminary consent form if agreeable. This form would be 
kept in their notes to prevent unnecessary contact and effort if a recipient declined. 
The admitting doctor could reconfirm this on admission for transplant prior to 
randomisation. Once consent was confirmed, the doctor would also be responsible 
for randomisation, completing the paperwork, taking any preliminary bloods and 
organising the infusion.  
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It may be unreasonable to ask the admitting doctor to complete large volumes of 
paperwork in addition to their usual duties so, provided the initial eligibility 
questions had been recorded, another individual, such as a research nurse, could 
complete other paperwork in daytime hours.  
 
A solution to randomisation would be to have a web based system that could be 
accessed by all the centres to allow different doctors to recruit and give infusions. 
This was too expensive for HOT but appropriate for HOT2 to ensure safe, 
transparent practice. It is probably also appropriate to have a web-based database for 
immediate data entry, which could be overseen by the designated researcher 
responsible for the trial. The designated person responsible for the trial must be a 
doctor but a specialist nurse could perform the day-to-day management and ERI has 
a successful track record of this process.  
 
It is clear that HA upregulates HO-1 and therefore it will not be necessary for all 
HOT2 participants to have PBMC HO-1 protein and mRNA extracted and tested. If 
clarification of HO-1 upregulation is required, then a reduced, confirmatory analysis 
could be performed. HOT2 may require a lab-based, blinded technician to organise 
specimens, carry out the experiments and record the results but there is capacity at 
the local research institute for this. 
 
It is not known whether dialysis removes HA from the circulation although after 
discussion with an expert, it was considered unlikely. However to be safe, HA was 
always given post dialysis. Unless this issue is clarified, HA will still need to be 
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given post dialysis and due to its potential toxicity to vessels, it must be given into a 
large vein. Therefore, one way to simplify the protocol is to give the infusion in 
theatre post-induction. This would ensure that HA was always given in a controlled 
manner into the central line, which is usually inserted by the anaesthetist at the start 
of the procedure.  
 
The HOT study protocol gave two doses of HA and the licence for treatment of 
porphyria allows a maximum of four doses. Therefore, it may be appropriate to 
increase the dose of HA to investigate if DGF is dose-dependent. This may be 
limited by appropriate venous access but if the numbers of participants was 
sufficient, the study could subgroup patients into different dosing regimes.  
 
The HOT2 protocol would not require a renal tissue biopsy. The biopsy was 
problematic to both participants and researchers and we do not consider the results to 












This MD concludes that HA is safe and effective in renal transplant recipients as 
reported in a phase II, randomised, placebo controlled, blinded, single-centre study. 
The primary outcome was achieved and demonstrated for the first time that HA 
induces HO-1 in peripheral and renal macrophages in kidney transplant recipients.  
 
There was also evidence that HA increased HO-1 expression in renal tissue. There 
was no evidence that HA improved renal function or reduced injury as seen in animal 
models but it is recognised that the sample size was small and the study was not 
powered to these endpoints. 
 
Larger studies are planned to determine the impact of HO-1 upregulation on clinical 
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